LOAN AND SECURITY AGREEMENT
Exhibit 10.14
THIS LOAN AND SECURITY AGREEMENT is made and dated as of December 22, 2011 and is entered into by and between CONCERT PHARMACEUTICALS, INC., a Delaware corporation, and each of its subsidiaries other than Concert Pharmaceuticals Securities Corporation, (hereinafter collectively referred to as the “Borrower”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”).
RECITALS
A. Borrower has requested Lender to make available to Borrower a loan in an aggregate principal amount of up to $20,000,000 (the “Term Loan”); and
B. Lender is willing to make the Term Loan on the terms and conditions set forth in this Agreement.
AGREEMENT
NOW, THEREFORE, Borrower and Lender agree as follows:
SECTION 1. DEFINITIONS AND RULES OF CONSTRUCTION
1.1 Unless otherwise defined herein, the following capitalized terms shall have the following meanings:
“Account Control Agreement(s)” means any agreement entered into by and among the Lender, Borrower and a third party Bank or other institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which grants Lender a perfected first priority security interest in the subject account or accounts.
“ACH Authorization” means the ACH Debit Authorization Agreement in substantially the form of Exhibit H.
“Advance(s)” means a Term Advance.
“Advance Date” means the funding date of any Advance.
“Advance Request” means a request for an Advance submitted by Borrower to Lender in substantially the form of Exhibit A.
“Agreement” means this Loan and Security Agreement, as amended from time to time.
“Assignee” has the meaning given to it in Section 11.13.
1
“Borrower Products” means all products, technical data or technology currently being developed, manufactured or sold by Borrower or which Borrower intends to sell, manufacture, license, or distribute in the future including any products or service offerings under development, collectively, together with all products, technical data or technology that have been sold, developed, licensed or distributed by Borrower since its incorporation.
“Cash” means all cash and liquid funds.
“Change in Control” means any (i) reorganization, recapitalization, consolidation or merger (or similar transaction or series of related transactions) of Borrower in which the holders of Borrower’s outstanding shares immediately before consummation of such transaction or series of related transactions (together with any affiliates of such holders) do not, immediately after consummation of such transaction or series of related transactions, retain shares representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly owned by such parent), in each case without regard to whether Borrower is the surviving entity, or (ii) sale or issuance by Borrower of new shares of Preferred Stock of Borrower to investors, none of whom are current investors in Borrower (or their affiliates), representing more than fifty percent (50%) of the voting power of the surviving entity (or the parent of such surviving entity if such surviving entity is wholly owned by such parent); provided, however, none of (a) an Initial Public Offering or (b) a bona fide equity financing for the purpose of raising capital from institutional investors reasonably acceptable to Lender, shall not constitute a Change in Control.
“Claims” has the meaning given to it in Section 11.10.
“Closing Date” means the date of this Agreement.
“Collateral” means the property described in Section 3.
“Commitment Fee” means $20,000, which fee Lender received prior to the Closing Date, and shall be deemed fully earned on such date regardless of the early termination of this Agreement.
“Confidential Information” has the meaning given to it in Section 11.12.
“Contingent Obligation” means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i) any Indebtedness of another, including any such obligation guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed to be an amount
2
equal to the stated or determined amount of the primary obligation described in clauses (i) and (ii) above in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support arrangement.
“Copyright License” means any written agreement granting any right to use any Copyright or Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.
“Copyrights” means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof, or of any other country.
“Deposit Accounts” means any “deposit accounts,” as such term is defined in the UCC, and includes any checking account, savings account, or certificate of deposit.
“ERISA” is the Employee Retirement Income Security Act of 1974, and its regulations, as amended and in effect from time to time.
“Event of Default” has the meaning given to it in Section 9.
“Facility Charge” means 0.75% of the Maximum Term Loan Amount.
“Financial Statements” has the meaning given to it in Section 7.1.
“GAAP” means generally accepted accounting principles in the United States of America, as in effect from time to time, provided that the parties agree that GAAP as in effect on the date of this Agreement shall be applicable for the interpretation of “capital lease obligations” in the definition of “Indebtedness”, unless the parties otherwise agree in writing.
“Grant Document” means an instrument or agreement providing that the Borrower or another Person or both shall provide funding for or share the costs of programs identified in such instruments or agreements entered into in the OCB.
“Grant Requirements” means all obligations of Borrower to provide funding for or share the costs of, programs identified in Grant Documents or to perform other obligations thereunder.
“GSK Agreement” means that certain Research and Development Collaboration and License Agreement by and between Glaxo Group Limited and Concert Pharmaceuticals dated May 29, 2009, as amended.
“Indebtedness” means (a) all indebtedness for borrowed money or the deferred purchase price of property or services (excluding trade credit entered into in the ordinary course of business due within ninety (90) days), including reimbursement and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations.
3
“Initial Public Offering” means an initial firm commitment underwritten offering of Borrower’s common stock pursuant to a registration statement under the Securities Act of 1933 filed with and declared effective by the Securities and Exchange Commission.
“Insolvency Proceeding” is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments of all or substantially all of a Person’s assets for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other similar relief.
“Intellectual Property” means all of Borrower’s Copyrights; Trademarks; Patents; Licenses; trade secrets, proprietary information (including pre-clinical, clinical and other data) and inventions; mask works; Borrower’s applications therefor and reissues, extensions, or renewals thereof; and Borrower’s goodwill associated with any of the foregoing, together with Borrower’s rights to xxx for past, present and future infringement of Intellectual Property and the goodwill associated therewith.
“Interest Rate” means for any day a per annum rate of interest equal to the greater of either (i) 8.50% plus the United States Prime Rate as reported in The Wall Street Journal minus 5.25%, and (ii) 8.50%; provided, however, the Interest Rate shall in no case exceed 11.0% per annum.
“Investment” means any beneficial ownership (including stock, partnership or limited liability company interests) of or in any Person, or any loan, advance or capital contribution to any Person or the acquisition of all, or substantially all, of the assets of another Person.
“Joinder Agreements” means for each Subsidiary (other than Concert Pharmaceuticals Securities Corp.), a completed and executed Joinder Agreement in substantially the form attached hereto as Exhibit G.
“Lender” has the meaning given to it in the preamble to this Agreement.
“License” means any Copyright License, Patent License, Trademark License or other license of rights or interests from a third party.
“Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, xxxx, xxxx or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a security interest.
“Loan” means the Advances made under this Agreement.
4
“Loan Documents” means this Agreement, the Notes, the ACH Authorization, the Account Control Agreements, the Joinder Agreements, all UCC Financing Statements and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby (excluding the Warrant), as the same may from time to time be amended, modified, supplemented or restated.
“Material Adverse Effect” means an occurrence, on or after the date of the last set of audited financials, that has a material adverse effect upon: (i) the business, operations, properties, assets or condition (financial or otherwise) of the Borrower and its Subsidiaries, taken as a whole, other than an effect in and of itself reasonably attributable to (a) adverse results or delays in any nonclinical or clinical trial, including without limitation failure to demonstrate the desired safety or efficacy of any biologic or drug; (b) the denial, delay or limitation of approval of, or taking of any other regulatory action by, the United States Food and Drug Administration or any other governmental entity with respect to any biologic or drug; (c) a change in or discontinuation of a strategic partnership or other collaboration or license arrangement; or (d) a going concern qualification in a financial statement or audit report resulting solely from Borrower and its Subsidiaries having less than twelve months of cash; or (ii) the ability of Borrower to perform the Secured Obligations when due in accordance with the terms of the Loan Documents, or the ability of Lender to enforce any of its rights or remedies with respect to the Secured Obligations; or (iii) the Collateral or Lender’s Liens on the Collateral or the priority of such Liens, in each case, in the aggregate; it being understood that in the case of each of items (ii) and (iii) the effects listed in clauses (i)(a) through (d) of this definition shall be disregarded.
“Maturity Date” means July 1, 2015, provided Maturity Date will mean October 1, 2015 if the interest-only period is extended pursuant to Section 2.1(d).
“Maximum Term Loan Amount” means $20,000,000.
“Maximum Rate” shall have the meaning assigned to such term in Section 2.3.
“Note(s)” means a Term Note.
“OCB” means in the ordinary course of business and shall include collaboration or licensing transactions that are customary in the Borrower’s industry such as, or comparable with or lesser in scope than, the Borrower’s existing collaboration with GlaxoSmithKline.
“Patent License” means any written agreement granting any right with respect to any invention on which a Patent is in existence or a Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest.
“Patents” means all letters patent of, or rights corresponding thereto, in the United States or in any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States or any other country.
“Permitted Indebtedness” means: (i) Indebtedness of Borrower arising under this Agreement or any other Loan Document; (ii) Indebtedness existing on the Closing Date which is disclosed in Schedule 1A; (iii) Indebtedness in the principal amount of up to $200,000
5
outstanding at any time secured by a lien described in clause (vii) of the defined term “Permitted Liens,”; (iv) Indebtedness to trade creditors incurred in the ordinary course of business, including Indebtedness incurred in the ordinary course of business with corporate credit cards; (v) Indebtedness that also constitutes a Permitted Investment; (vi) Subordinated Indebtedness; (vii) reimbursement obligations in connection with letters of credit that are secured by cash or cash equivalents and issued on behalf of the Borrower or a Subsidiary thereof in an amount not to exceed $906,000 at any time outstanding; (viii) other Indebtedness in an amount not to exceed $250,000 at any time outstanding; (ix) Contingent Obligations of up to $200,000 described on clause (iii) of the definition of Contingent Obligations entered into to mitigate risk and not for speculative purposes; (x) Grant Requirements; (xi) Indebtedness among Borrowers or of Borrower to any non-Borrower Subsidiary; and (xii) extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be.
“Permitted Investment” means: (i) Investments existing on the Closing Date which are disclosed in Schedule 1B; (ii) (a) marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing within twenty four months from the date of acquisition thereof, (b) commercial paper maturing no more than 270 days from the date of creation thereof and at the time of the Investment having a rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Xxxxx’x Investors Service, (c) certificates of deposit issued by any bank with assets of at least $500,000,000 maturing no more than twenty four months from the date of investment therein, (d) money market accounts; and (e) corporate debt obligations maturing no more than 24 months from the date of acquisition thereof and at the time of investment having a rating of at least A3 or A- from either Standard & Poors or Xxxxx’x Investor Service; (iii) repurchases of stock from former employees, directors, or consultants of Borrower under agreements approved by the Borrower’s board of directors in an aggregate amount not to exceed $250,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or would exist after giving effect to the repurchases; (iv) Investments accepted in connection with Permitted Transfers; (v) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business; (vi) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not affiliates, in the ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments of Borrower in any Subsidiary; (vii) Investments consisting of loans not involving the net transfer on a substantially contemporaneous basis of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee stock purchase plans or other similar agreements approved by Borrower’s Board of Directors; (viii) Investments consisting of travel advances or moving expenses in the ordinary course of business; (ix) Investments in existing or newly-formed Subsidiaries organized in the United States, provided that such Subsidiaries enter into a Joinder Agreement and execute such other documents as shall be reasonably requested by Lender and de minimis Investments in Concert Pharmaceuticals Securities Corporation in connection with its liquidation or dissolution; (x) Investments in subsidiaries organized outside of the United States approved in advance in writing by Lender; (xi) licenses, joint ventures, collaboration agreements, strategic alliances and
6
similar arrangements in the OCB providing for the exclusive or nonexclusive licensing of technology, Intellectual Property, or Borrower Products, the development of technology, Intellectual Property or Borrower Products, the assignment of ownership or co-ownership rights in connection with the foregoing, or the providing of technical support, provided that any cash Investments by Borrower in another Person (other than a Subsidiary that has entered into a Joinder pursuant to the terms hereof) as part of the foregoing do not exceed $100,000 in the aggregate in any fiscal year; (xii) Investments made pursuant to any investment policy adopted by a Borrower after the Closing Date and approved by Lender; (xiii) Investments of up to $200,000 in the aggregate at any time outstanding in connection with Grant Requirements; (xiv) Investments by Borrower in another Borrower; and (xv) additional Investments that do not exceed $250,000 in the aggregate per fiscal year.
“Permitted Liens” means any and all of the following: (i) Liens in favor of Lender; (ii) Liens existing on the Closing Date which are disclosed in Schedule 1C; (iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings; provided, that Borrower maintains adequate reserves therefor in accordance with GAAP; (iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like Persons arising in the ordinary course of Borrower’s business and imposed without action of such parties; provided, that the payment thereof is not yet required; (v) Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default hereunder; (vi) the following deposits, to the extent made in the ordinary course of business: deposits under worker’s compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than liens arising under ERISA or environmental liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds; (vii) Liens on Equipment or software, other intellectual property, or other capital assets, constituting purchase money liens and liens in connection with capital leases securing Indebtedness permitted in clause (iii) of “Permitted Indebtedness”; (viii) Liens incurred in connection with Subordinated Indebtedness; (ix) leasehold interests in leases or subleases and licenses granted in the OCB and not interfering in any material respect with the business of the licensor; (x) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; (xi) Liens on insurance proceeds securing the payment of financed insurance premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); (xii) statutory, common law and contractual rights of set-off and other similar rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; (xiii) easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business so long as they do not materially impair the value or marketability of the related property; (xiv) Liens on cash or cash equivalents securing obligations permitted under clause (vii) of the definition of Permitted Indebtedness; (xv) Liens in connection with operating leases in the Equipment that is the subject of such leases; (xvi) Permitted Transfers; and (xvii) Liens incurred in connection with the extension, renewal or refinancing of the indebtedness secured by Liens of the type described in
7
clauses (i) through (xvi) above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon) does not increase.
“Permitted Transfers” means (i) sales of Inventory in the normal course of business, (ii) exclusive or non-exclusive licenses, joint ventures, collaboration agreements, strategic alliances and similar arrangements in the OCB providing for the exclusive or nonexclusive licensing of technology, Intellectual Property or Borrower Products, the development of technology, Intellectual Property or Borrower Products, the assignment of ownership or co-ownership rights in connection with the foregoing, or the providing of technical support, (iii) dispositions of worn-out, obsolete or surplus Equipment at fair market value in the ordinary course of business, (iv) Permitted Investments, (v) Permitted Liens, (vi) dispositions of Copyright rights in connection with publications in scientific journals, and (vii) other Transfers of assets having a fair market value of not more than $250,000 in the aggregate in any fiscal year.
“Person” means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, other entity or government.
“Preferred Stock” means at any given time any equity security issued by Borrower that has any rights, preferences or privileges senior to Borrower’s common stock.
“Prepayment Charge” shall have the meaning assigned to such term in Section 2.5.
“Receivables” means all of Borrower’s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters of credit, proceeds of any letter of credit, and Letter of Credit Rights.
“Secured Obligations” means Borrower’s obligations under this Agreement and any Loan Document, including any obligation to pay any amount now owing or later arising.
“Subordinated Indebtedness” means Indebtedness subordinated to the Secured Obligations in amounts and on terms and conditions satisfactory to Lender in its sole discretion.
“Subsidiary” means an entity, whether corporate, partnership, limited liability company, joint venture or otherwise, in which Borrower owns or controls more than 50% of the outstanding voting securities, including each entity listed on Schedule 1 hereto.
“Term Advance” means any Term Loan funds advanced under this Agreement.
“Term Note” means a Promissory Note in substantially the form of Exhibit B-1.
8
“Trademark License” means any written agreement granting any right to use any Trademark or Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.
“Trademarks” means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof.
“UCC” means the Uniform Commercial Code as the same is, from time to time, in effect in the Commonwealth of Massachusetts; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Lender’s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the Commonwealth of Massachusetts, then the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions.
“Warrant” means the warrant entered into in connection with the Loan.
Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,” “subsection,” “Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. Unless otherwise specifically provided herein, any accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP, consistently applied. Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC.
SECTION 2. THE LOAN
2.1 Term Loan.
(a) Advances. Subject to the terms and conditions of this Agreement, Lender will make, and Borrower agrees to draw, a Term Advance of $7,500,000 (the “First Tranche”) on the Closing Date. Beginning on the Closing Date, and continuing through March 31, 2012, Borrower may request one additional Term Advance in an aggregate amount up to $12,500,000 (the “Second Tranche”). The aggregate outstanding Term Advances may be up to the Maximum Term Loan Amount.
(b) Advance Request. To obtain a Term Advance, Borrower shall complete, sign and deliver an Advance Request (which, as to the Second Tranche, shall be at least five business days before the Advance Date) and Term Note to Lender. Lender shall fund the Term Advance in the manner requested by the Advance Request provided that each of the conditions precedent in Section 4 of this Agreement applicable to such Term Advance is satisfied as of the requested Advance Date.
9
(c) Interest. The principal balance of each Term Advance shall bear interest thereon from such Advance Date at the Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed. The Interest Rate will float and change on the day the Prime Rate changes from time to time.
(d) Payment. Borrower will pay interest on each Term Advance in arrears on the first business day of each month, beginning the month after the Advance Date and ending on January 3, 2013 (the “Interest Only Period”). Borrower shall repay the aggregate Term Loan principal balance that is outstanding on the first anniversary of the Closing Date in 30 equal monthly installments of principal and interest beginning February 1, 2013 and continuing on the first business day of each month thereafter. Notwithstanding the foregoing, Borrower may elect to postpone the date on which the first such installment is due until May 1, 2013, (and the last payment date of the Interest Only Period shall be April 1, 2013), provided Borrower has begun the Proof of Concept study for CTP-499, meaning that the first patient has been enrolled in a clinical study in which subjects with diabetes and reduced kidney function are randomly assigned to receive either placebo or CTP-499 treatment. The entire Term Loan principal balance and all accrued but unpaid interest hereunder, shall be due and payable on Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the Borrower’s account as authorized on the ACH Authorization on each payment date of all periodic obligations payable to Lender under each Term Note or Term Advance.
2.2 Maximum Interest. Notwithstanding any provision in this Agreement, the Notes, or any other Loan Document, it is the parties’ intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the Commonwealth of Massachusetts shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum Rate”). If a court of competent jurisdiction shall finally determine that Borrower has actually paid to Lender an amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually paid by Borrower shall be applied as follows: first, to the payment of principal outstanding on the Notes; second, after all principal is repaid, to the payment of Lender’s accrued interest, costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower.
2.3 Default Interest. In the event any payment is not paid on the scheduled payment date, an amount equal to five percent (5%) of the past due amount shall be payable on demand. Upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set
10
forth in Section 2.1(c) plus five percent (5%) per annum. In the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth in Section 2.1(c).
2.4 Prepayment. At its option upon at least 7 business days prior notice to Lender, Borrower may prepay all, but not less than all, of the outstanding Advances by paying the entire principal balance, all accrued and unpaid interest, together with a prepayment charge equal to the following percentage of the Advance amount being prepaid: if such Advance amounts are prepaid in any of the first twelve (12) months following the Closing Date, 3.0%; after twelve (12) months but prior to twenty four (24) months, 2.0%; and thereafter, 1.0% (each, a “Prepayment Charge”). Borrower agrees that the Prepayment Charge is a reasonable calculation of Lender’s lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early repayment of the Advances. Borrower shall prepay the outstanding amount of all principal and accrued interest through the prepayment date and the Prepayment Charge upon demand of the Lender made no later than 30 days following a Change in Control.
SECTION 3. SECURITY INTEREST
3.1 As security for the prompt and complete payment when due (whether on the payment dates or otherwise) of all the Secured Obligations, Borrower grants to Lender a security interest in all of Borrower’s personal property now owned or hereafter acquired, including the following (collectively, the “Collateral”): (a) Receivables; (b) Equipment; (c) Fixtures; (d) General Intangibles (other than Intellectual Property); (e) Inventory; (f) Investment Property (but excluding thirty-five percent (35%) of the capital stock of any foreign Subsidiary that constitutes a Permitted Investment); (g) Deposit Accounts; (h) Cash; (i) Goods; and other tangible and intangible personal property of Borrower whether now or hereafter owned or existing, or acquired by, Borrower and wherever located; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing. Notwithstanding any of the foregoing, the Collateral shall not under any circumstance include, and no security interest is granted in (i) Borrower’s Intellectual Property, provided, however, that the Collateral shall include all Accounts and General Intangibles that consist of rights to payment and proceeds from the sale, licensing or disposition of all or any part, or rights in, the Borrower’s Intellectual Property (the “Rights to Payment”); (ii) any capital stock of any foreign subsidiary that constitutes a Permitted Investment in excess of 65% of such capital stock, provided that Lender’s taking a security interest in more than 65% of such stock would be reasonably expected to cause Borrower to incur adverse tax consequences; (iii) any assets of Borrower that both (x) consist of compounds and raw materials used to manufacture biopharmaceuticals or which are used for preclinical testing or clinical trials, and (y) are located outside of the United States, if and for so long as the grant of such security interest is prohibited by or requires a consent under any applicable requirement of law of a jurisdiction other than the United States or any state or other subdivision thereof, provided that the Borrower shall not be required to undertake any steps under the laws of any applicable foreign jurisdiction with respect to the creation, perfection or priority of the Secured Party’s security interests in such assets; (iv) equipment
11
financed by capital leases or purchase money financing and all Borrower’s books and records relating to the foregoing, and any and all claims, rights and interest in such assets and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing; and (v) any cash or cash equivalents described in clause (vii) of the definition of Permitted Indebtedness. Notwithstanding the foregoing, if a judicial authority (including a U.S. Bankruptcy Court) holds that a security interest in the underlying Intellectual Property is necessary to have a security interest in the Rights to Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include the Intellectual Property to the extent necessary to permit perfection of Lender’s security interest in the Rights to Payment, except to the extent that such inclusion as Collateral could be inconsistent with or conflict with the GSK Agreement or any agreement entered into in connection with a Permitted Transfer or interfere with the parties’ rights and remedies thereunder.
SECTION 4. CONDITIONS PRECEDENT TO LOAN
The obligations of Lender to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions:
4.1 Initial Advance. On or prior to the Closing Date, Borrower shall have delivered to Lender the following:
(a) executed originals of the Loan Documents, Account Control Agreements, a legal opinion of Borrower’s counsel, and all other documents and instruments reasonably required by Lender to effectuate the transactions contemplated hereby or to create and perfect the Liens of Lender with respect to all Collateral, in all cases in form and substance reasonably acceptable to Lender;
(b) certified copy of resolutions of Borrower’s board of directors evidencing approval of (i) the Loan and other transactions evidenced by the Loan Documents; and (ii) the Warrant and transactions evidenced thereby;
(c) certified copies of the Certificate of Incorporation and the Bylaws, as amended through the Closing Date, of Borrower;
(d) a certificate of good standing for Borrower from its state of incorporation and similar certificates from all other jurisdictions in which it does business and where the failure to be qualified would have a Material Adverse Effect;
(e) payment of the Facility Charge and reimbursement of Lender’s current expenses reimbursable pursuant to this Agreement, which amounts may be deducted from the initial Advance; and
(f) such other documents as Lender may reasonably request.
12
4.2 All Advances. On each Advance Date:
(a) Lender shall have received an Advance Request and a Note for the relevant Advance as required by Section 2.1(b), as applicable, each duly executed by Borrower’s Chief Executive Officer, Chief Operating Officer or Chief Financial Officer.
(b) The representations and warranties set forth in this Agreement and in Section 5 of this Agreement shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date.
(c) Borrower shall be in compliance in all material respects with all the terms and provisions set forth herein and in each other Loan Document on its part to be observed or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred and be continuing.
(d) Each Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance Request.
4.3 No Default. As of the Closing Date and each Advance Date, as applicable, (i) no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default and (ii) no Material Adverse Effect has occurred and is continuing.
SECTION 5. REPRESENTATIONS AND WARRANTIES OF BORROWER
Borrower represents and warrants that:
5.1 Corporate Status. Borrower is a corporation duly organized, legally existing and in good standing under the laws of the State of Delaware, and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have a Material Adverse Effect. Borrower’s present name, former names (if any), owned and leased locations, place of formation, tax identification number, organizational identification number and other information are correctly set forth in Exhibit C, as may be updated by Borrower in a written notice (including any Compliance Certificate) provided to Lender after the Closing Date.
5.2 Collateral. Borrower owns its property, free of all Liens, except for Permitted Liens. Borrower has the corporate power and authority to grant to Lender a Lien in the Collateral as security for the Secured Obligations.
5.3 Consents. Borrower’s execution, delivery and performance of the Notes, this Agreement and all other Loan Documents, and Borrower’s execution of the Warrant, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted
13
Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do not violate any provisions of Borrower’s Certificate of Incorporation, bylaws, or any material law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject and (iv) except as described on Schedule 5.3, do not violate any material contract or agreement or require the consent or approval of any other Person that has not been obtained. The individual or individuals executing the Loan Documents and the Warrant on behalf of the Borrower are duly authorized to do so.
5.4 Material Adverse Effect. No Material Adverse Effect has occurred and is continuing.
5.5 Actions Before Governmental Authorities. Except as described on Schedule 5.5, there are no actions, suits or proceedings at law or in equity by or before any governmental authority now pending or, to the knowledge of Borrower, threatened in writing against or affecting Borrower or its property as to which there is a reasonable likelihood of an adverse determination and which, if adversely determined, would reasonably be expected to, individually or in the aggregate, result in a Material Adverse Effect.
5.6 Laws; Agreements. Borrower is not in violation of any law, rule or regulation, or in default with respect to any judgment, writ, injunction or decree of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect. Borrower is not in default in any manner under any provision of any agreement or instrument evidencing Indebtedness, or any other material agreement to which it is a party or by which it is bound, and which default would reasonably be expected to have a Material Adverse Effect.
5.7 Information Correct and Current. No report, Advance Request, financial statement, exhibit or schedule furnished, by or on behalf of Borrower to Lender in connection with any Loan Document or included therein or delivered pursuant thereto, when taken together with all such other reports, statements or other documents or writings, contains any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they are made, not misleading at the time such statement was made or deemed made. Additionally, any and all financial or business projections provided by Borrower to Lender shall be at the time delivered (i) provided in good faith and based on the most current data and information available to Borrower, and (ii) the most current of such projections provided to Borrower’s Board of Directors.
5.8 Tax Matters. Except as described on Schedule 5.8, (a) Borrower has filed all material federal, state and local tax returns that it is required to file (or extensions thereof), (b) Borrower has duly paid or fully reserved (if required under GAAP) for all material taxes or installments thereof (including any interest or penalties) as and when due, which have or may become due pursuant to such returns, and (c) Borrower has paid or fully reserved for any material tax assessment received by Borrower for the three (3) years preceding the Closing Date, if any (including any taxes being contested in good faith and by appropriate proceedings).
14
5.9 Intellectual Property Claims. Except for Permitted Liens, Borrower is the sole owner of, or otherwise has the right to use, the Intellectual Property material to its business. Except as described on Schedule 5.9,(i) to Borrower’s knowledge, each of the material issued Copyrights, Trademarks and Patents is valid and enforceable, (ii) no material Intellectual Property of Borrower has been judged by a decision of a court of competent jurisdiction, invalid or unenforceable, in whole or in part, and (iii) no claim has been made to Borrower in writing that any material Intellectual Property of Borrower violates the rights of any third party except to the extent such claim would not reasonably be expected to cause a Material Adverse Effect. Exhibit D is a true, correct and complete list of each of Borrower’s Patents, registered Trademarks, registered Copyrights, and material agreements under which Borrower licenses Intellectual Property from third parties (shrink-wrap software licenses and click on license agreements, open source code and other licenses available to the public without customization shall not be considered a material License or agreement), together with application or registration numbers, as applicable, owned by Borrower or any Subsidiary, in each case as of the Closing Date. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the foregoing contracts, licenses or agreements and, to Borrower’s knowledge, no third party to any such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder in each case which would reasonably be expected to have a Material Adverse Effect.
5.10 Intellectual Property. Except as described on Schedule 5.10, Borrower has, or in the case of any proposed business, will have, all material rights with respect to Intellectual Property necessary in the operation or conduct of Borrower’s business as currently conducted and proposed to be conducted by Borrower. Without limiting the generality of the foregoing, other than in connection with Permitted Transfers, and in the case of material in-bound Licenses, except for restrictions that are unenforceable under Division 9 of the UCC and except as provided in the GSK Agreement, Borrower has the right, to the extent required to operate Borrower’s business, to freely transfer, license or assign the Intellectual Property licensed pursuant to such material License without condition, restriction or payment of any kind (other than payments in the ordinary course of business) to any third party, Borrower owns or has the right to use, pursuant to valid licenses, all material software development tools, library functions, compilers and other third-party software and other items that are necessary for the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products that are currently being clinically developed, manufactured or sold by Borrower. For the avoidance of doubt, shrink-wrap licenses, click on license agreements, open source code and other licenses available to the public without customization shall not be considered a material License.
5.11 Borrower Products. Except as described on Schedule 5.11, no material Intellectual Property owned by Borrower or Borrower Product has been or is subject to any actual or, to the knowledge of Borrower, threatened (in writing) litigation, inter-party proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding decree, order, judgment, settlement agreement or stipulation that restricts in any material respect Borrower’s use,
15
transfer or licensing thereof or that may affect the validity, use or enforceability thereof. To Borrower’s knowledge, there is no decree, order, judgment, agreement, stipulation, arbitral award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or ownership interest in any future material Intellectual Property related to the operation or conduct of the business of Borrower or Borrower Products. Borrower has not received any written notice or claim challenging Borrower’s ownership in any material Intellectual Property (or written notice of any claim challenging the ownership in any material licensed Intellectual Property of the owner thereof) or suggesting that any third party has any claim of legal or beneficial ownership with respect thereto. To Borrower’s knowledge, neither Borrower’s use of its material Intellectual Property nor the production and sale of Borrower Products infringes in any material respect the Intellectual Property or other rights of others.
5.12 Financial Accounts. Exhibit E, as may be updated by the Borrower in a written notice provided to Lender after the Closing Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies in all material respects the name, address and telephone number of each bank or other institution, the name in which the account is held, and the complete account number therefor.
5.13 Employee Loans. Except as permitted as a Permitted Investment, Borrower has no outstanding loans to any employee, officer or director of the Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of the Borrower by a third party.
5.14 Capitalization and Subsidiaries. Borrower’s capitalization as of the Closing Date is set forth on Schedule 5.14 annexed hereto. Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments. Attached as Schedule 5.14, as may be updated by Borrower in a written notice provided after the Closing Date, is a true, correct and complete list of each Subsidiary.
SECTION 6. INSURANCE; INDEMNIFICATION
6.1 Coverage. Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence form, against risks customarily insured against in Borrower’s line of business. Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms of the indemnification agreement found in Section 6.3. Borrower must maintain a minimum of $2,000,000 of commercial general liability insurance (including umbrella coverage) for each occurrence. Borrower has and agrees to maintain a minimum of $2,000,000 of directors and officers’ insurance for each occurrence and $5,000,000 in the aggregate. So long as there are any Secured Obligations outstanding, Borrower shall also cause to be carried and maintained insurance upon the Collateral, insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject to standard exceptions and deductibles. Borrower shall also carry and maintain a fidelity insurance policy in an amount not less than $100,000.
16
6.2 Certificates. Borrower shall deliver to Lender certificates of insurance that evidence Borrower’s compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2. Borrower’s insurance certificate shall state Lender is an additional insured for commercial general liability, an additional insured and a loss payee for all risk property damage insurance, subject to the insurer’s approval, a loss payee for fidelity insurance, and a loss payee for property insurance and additional insured for liability insurance for any future insurance that Borrower may acquire from such insurer. Attached to the certificates of insurance will be additional insured endorsements for liability and lender’s loss payable endorsements for all risk property damage insurance and fidelity. All certificates of insurance will provide for a minimum of thirty (30) days advance written notice to Lender of cancellation (except for 10 days for non payment). Any failure of Lender to scrutinize such insurance certificates for compliance is not a waiver of any of Lender’s rights, all of which are reserved.
6.3 Indemnity. Borrower agrees to indemnify and hold Lender and its officers, directors, employees, agents, in-house attorneys, representatives and shareholders harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in tort, including strict liability in tort), including reasonable attorneys’ fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal), that may be instituted or asserted against or incurred by Lender or any such Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases claims resulting from Lender’s or any indemnitee’s gross negligence or willful misconduct. Borrower agrees to pay, and to save Lender harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales or other similar taxes (excluding taxes imposed on or measured by the net income of Lender) that may be payable or determined to be payable with respect to any of the Collateral or this Agreement; provided, however, that (i) with respect to such liabilities imposed originally and independently on Lender, Lender shall notify a Borrower of any such liabilities within 180 days of the initial date Lender had actual knowledge of Lender’s direct exposure to such liabilities, and (ii) with respect to all other such liabilities not described in subsection (i), Lender shall notify Borrower of any such liabilities within 180 days of the initial date Lender has actual knowledge of its direct exposure to such liabilities.
SECTION 7. COVENANTS OF BORROWER
Borrower agrees as follows:
7.1 Financial Reports. Borrower shall furnish to Lender the financial statements and reports listed hereinafter (the “Financial Statements”):
(a) as soon as practicable (and in any event within 30 days) after the end of each month, unaudited interim and year-to-date financial statements as of the end of such month (prepared on a consolidated basis, if applicable), including balance sheet and related statements of income and cash flows, all certified on behalf of Borrower by Borrower’s Chief Executive Officer, Chief Operating Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments, (iii) they do not contain certain non-cash items, and (iv) that they are subject to adjustment with respect to revenue recognition for upfront and milestone payments.
17
(b) as soon as practicable (and in any event within 45 days) after the end of each of the first three calendar quarters of each year (I) unaudited interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated basis, if applicable), including balance sheet and related statements of income and cash flows, certified on behalf of Borrower by Borrower’s Chief Executive Officer, Chief Operating Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments, (iii) they do not contain certain non-cash items, and (iv) that they are subject to adjustment with respect to revenue recognition for upfront and milestone payments; and (II) before an Initial Public Offering, the most recent capitalization table for Borrower, including the weighted average exercise price of employee stock options.
(c) (I) as soon as practicable and in any event within sixty (60) days after the end of each fiscal year, preliminary financial statements as of the end of such fiscal year (prepared on a consolidated basis, if applicable), including balance sheet and related statements of income and cash flows, certified on behalf of Borrower by Borrower’s Chief Executive Officer, Chief Operating Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments, (iii) they do not contain certain non-cash items, and (iv) that they are subject to adjustment with respect to revenue recognition for upfront and milestone payments; (II) before an Initial Public Offering, as soon as practicable and in any event within sixty (60) days after the end of each fiscal year, the most recent capitalization table for Borrower, including the weighted average exercise price of employee stock options; and (III) as soon as practicable and in any event within one hundred eighty (180) days) after the end of each fiscal year, audited financial statements as of the end of such year (prepared on a consolidated basis, if applicable), including balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Lender, accompanied by an audit report from such accountants which is unqualified as to scope of audit;
(d) as soon as practicable (and in any event within 30 days) after the end of each month, a Compliance Certificate in the form of Exhibit F;
18
(e) promptly after the sending or filing thereof, as the case may be, copies of any proxy statements, financial statements or reports that Borrower has made available generally to holders of its Preferred Stock and copies of any regular, periodic and special reports or registration statements that Borrower files with the Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange;
(f) Before an Initial Public Offering, at the same time and in the same manner as it gives to its Board of Directors, copies of all notices, minutes, consents and other materials that Borrower provides to its Board of Directors in connection with meetings of the Board of Directors, and minutes of such meetings, provided Borrower may exclude from such delivery any materials, the disclosure of which would reasonably be expected to constitute or effect a waiver of the attorney-client privilege;
(g) financial and business projections promptly following their approval by Borrower’s Board of Directors, as well as budgets, operating plans; and
(h) other financial information reasonably requested by Lender.
Borrower shall not make any change in its fiscal years or fiscal quarters or, without notice to Lender, any change in its accounting policies or reporting practices. The fiscal year of Borrower shall end on December 31.
The executed Compliance Certificate may be sent via facsimile to Lender at (000) 000-0000 or via e-mail to jbourque @xxxxxxxxxxxx.xxx. All Financial Statements required to be delivered pursuant to clauses (a), (b) and (c) shall be sent via e-mail to xxxxxxxxxxxxxxxxxxx@xxxxxxxxxxxx.xxx with a copy to xxxxxxxx@xxxxxxxxxxxx.xxx provided, that if e-mail is not available or sending such Financial Statements via e-mail is not possible, they shall be sent via facsimile to Lender at: (000) 000-0000, attention Chief Credit Officer.
7.2 Management Rights. Borrower shall permit any representative that Lender authorizes, including its attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable notice during normal business hours (but in any event no more than once in any12-month period unless an Event of Default has occurred and is continuing). In addition, any such representative shall have the right to meet with management and officers of Borrower to discuss such books of account and records. In addition, Lender shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower concerning significant business issues affecting Borrower. Such consultations shall not unreasonably interfere with Borrower’s business operations. The parties intend that the rights granted Lender shall constitute “management rights” within the meaning of 29 C.F.R Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Lender with respect to any business issues shall not be deemed to give Lender, nor be deemed an exercise by Lender of, control over Borrower’s management or policies.
19
7.3 Further Assurances. Borrower shall from time to time execute, deliver and file, alone or with Lender, any financing statements, security agreements, collateral assignments, notices, control agreements, or other necessary documents to perfect or give to Lender a first priority Lien on the Collateral (subject to Permitted Liens). Borrower shall from time to time procure any instruments or documents as may be reasonably requested by Lender, and take all further action that may be necessary or desirable, or that Lender may reasonably request, to perfect and protect the Liens granted hereby and thereby. In addition, and for such purposes only, Borrower hereby authorizes Lender to execute and deliver on behalf of Borrower and to file such financing statements, collateral assignments, notices, control agreements, security agreements and other documents without the signature of Borrower either in Lender’s name or in the name of Lender as agent and attorney-in-fact for Borrower. Borrower shall in its reasonable business judgment protect and defend Borrower’s title to the Collateral and Lender’s Lien thereon against all Persons claiming any interest adverse to Borrower or Lender other than Permitted Liens.
7.4 Indebtedness. Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness at any time before the Maturity Date, except for the conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion.
7.5 Encumbrances. Borrower shall at all times keep its property free and clear from any Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice when the Borrower knows of any legal process affecting such property, or any Liens thereon. Borrower shall cause its Subsidiaries to protect and defend such Subsidiary’s title to its property from and against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary’s property free and clear from any Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written notice when the Borrower knows of any legal process affecting such Subsidiary’s property. Borrower shall not enter into any agreement with any Person other than Lender (other than in connection with Permitted Liens and Permitted Transfers) that has the effect of restricting Borrower from granting a Lien on its Intellectual Property to Lender.
7.6 Investments. Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries so to do, other than Permitted Investments.
7.7 Distributions. Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other equity interest other than (i) pursuant to employee, director or consultant repurchase plans or other similar agreements, in an aggregate amount not to exceed $250,000, or (ii) pursuant to Section 4 of the Third Amended and Restated Right of First Refusal and Co-Sale Agreement dated as of June 1, 2009 provided that any such repurchase is approved by the Borrower’s Board of Directors, in an aggregate amount not to exceed $500,000, (b) declare or pay any cash dividend or
20
make a cash distribution on any class of stock or other equity interest, except that a Subsidiary may pay dividends or make distributions to Borrower, or (c) lend money to any employees, officers or directors or guarantee the payment of any such loans granted by a third party other than Permitted Investments.
7.8 Transfers. Except for Permitted Transfers, Permitted Investments and Permitted Liens, Borrower shall not voluntarily or involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or legal interest in any material portion of their assets.
7.9 Mergers or Acquisitions. (a) Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than mergers or consolidations of a Subsidiary into another Subsidiary or into Borrower), (b) Borrower shall not acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person other than Permitted Investments. Borrower may dissolve any Subsidiary as long as the assets of that Subsidiary are promptly distributed to such Subsidiary’s shareholder.
7.10 Taxes. Borrower and its Subsidiaries shall pay when due all material taxes, fees or other charges of any nature whatsoever (together with any related interest or penalties) now or hereafter imposed or assessed against Borrower, Lender or the Collateral or upon Borrower’s ownership, possession, use, operation or disposition thereof or upon Borrower’s rents, receipts or earnings arising therefrom. Borrower shall file on or before the due date therefor all personal property tax returns (or extensions) in respect of the Collateral. Notwithstanding the foregoing, Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains adequate reserves therefor in accordance with GAAP.
7.11 Corporate Changes.
(a) Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of formation without twenty (20) days’ prior written notice to Lender.
(b) The Borrower shall not suffer a Change in Control.
(c) Neither Borrower nor any Subsidiary shall relocate its chief executive office or its principal place of business unless: (i) it has provided prior written notice to Lender; and (ii) such relocation shall be within the continental United States.
(d) Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other than (v) Borrower Products, including compounds and raw materials used to manufacture biopharmaceuticals or which are used for preclinical testing or clinical trials, in the ordinary course of business, (w) Permitted Transfers, (x) sales of Inventory in the ordinary course of business, (y) relocations of Equipment having an aggregate value of up to $150,000 in any fiscal year, and (z) relocations of Collateral from a location described on Exhibit C to another location described on Exhibit C) unless (i) it has
21
provided prompt written notice to Lender, (ii) such relocation is within the continental United States and, (iii) if such relocation is to a third party bailee, and the Collateral has a value in excess of $250,000, it has delivered a bailee agreement in form and substance reasonably acceptable to Lender.
7.12 Deposit Accounts. Neither Borrower nor any Subsidiary shall maintain any Deposit Accounts constituting Collateral (other than payroll accounts or accounts holding trust fund taxes), or accounts holding Investment Property constituting Collateral, except with respect to which Lender has an Account Control Agreement, if applicable.
7.13 Subsidiaries. Borrower shall notify Lender of each Subsidiary formed subsequent to the Closing Date and, within 15 days of formation, shall cause any such Subsidiary organized under the laws of any State within the United States to execute and deliver to Lender a Joinder Agreement.
SECTION 8. RESERVED
8.1 Reserved.
SECTION 9. EVENTS OF DEFAULT
The occurrence of any one or more of the following events shall be an Event of Default:
9.1 Payments. Borrower fails to pay any amount due under this Agreement, the Notes or any of the other Loan Documents on the due date, and in each case such default continues for more than 3 business days after the due date thereof; or
9.2 Covenants. Borrower breaches or defaults in the performance of any covenant under any of the Loan Documents, and (a) with respect to a default under any such covenant under this Agreement (other than under Sections 6.1, 7.5, 7.6, 7.7, 7.8, 7.9 or 7.11) such default continues for more than ten (10) business days after the earlier of the date on which (i) Lender has given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default, or (b) with respect to a default under any of Sections 6.1, 7.5, 7.6, 7.7, 7.8 or 7.9, (b) the occurrence of such default, or (c) with respect to a default under any of Sections 7.9(a) and 7.11(b), the Lender has given notice of such default to Borrower no later than 30 days after a Change of Control; or
9.3 Material Adverse Effect. An event has occurred that would reasonably be expected to have a Material Adverse Effect; or
9.4 Other Loan Documents. The occurrence of any default under any Loan Document, the Warrant or any other agreement between Borrower and Lender and such default continues for more than ten business (10) days after the earlier of (a) Lender has given notice of such default to Borrower, or (b) Borrower has actual knowledge of such default; or
22
9.5 Representations. Any representation or warranty made by Borrower in any Loan Document or in the Warrant shall have been false or misleading in any material respect; or
9.6 Insolvency. Borrower (A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to pay its debts as they become due, or be unable to pay the Secured Obligations under the Loan Documents, or shall become insolvent; or (iii) shall file a voluntary petition in bankruptcy; or (iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1/3% or more) of the assets or property of Borrower; or (vi) shall cease operations of its business as its business has normally been conducted for 3 consecutive business days, or terminate substantially all of its employees; or (vii) Borrower or its directors or majority shareholders shall take any action initiating any of the foregoing actions described in clauses (i) through (vi); or (B) either (i) sixty (60) days shall have expired after the commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (ii) a stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) Borrower shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or (v) forty five (45) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of Borrower without such appointment being vacated; or
9.7 Attachments; Judgments. Any portion of Borrower’s assets having a value in excess of $350,000 is attached or seized, or a levy is filed against any such assets, or a judgment or judgments (not covered by insurance as to which an insurer not affiliated with Borrower has acknowledged coverage) is/are entered for the payment of money, individually or in the aggregate, of at least $350,000, and remains unstayed, unbonded and unsatisfied for more than 30 days, or Borrower is enjoined or in any way prevented by court order from conducting any material part of its business; or
9.8 Other Obligations. The occurrence of any default under any agreement or obligation of Borrower involving any Indebtedness in excess of $175,000.
SECTION 10. REMEDIES
10.1 General. Upon and during the continuance of any one or more Events of Default, (i) Lender may, at its option, accelerate and demand payment of all or any part of the Secured Obligations together with a Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of
23
the type described in Section 9.6, the Notes and all of the Secured Obligations shall automatically be accelerated and made due and payable, in each case without any further notice or act), and (ii) Lender may notify any of Borrower’s account debtors to make payment directly to Lender, compromise the amount of any such account on Borrower’s behalf and endorse Lender’s name without recourse on any such payment for deposit directly to Lender’s account. Lender may exercise all rights and remedies with respect to the Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and commingle the Collateral. All Lender’s rights and remedies shall be cumulative and not exclusive.
10.2 Collection; Foreclosure. Upon the occurrence and during the continuance of any Event of Default, Lender may, at any time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in such order as Lender may elect. Any such sale may be made either at public or private sale at its place of business or elsewhere. Borrower agrees that any such public or private sale may occur upon ten (10) calendar days’ prior written notice to Borrower. Lender may require Borrower to assemble the Collateral and make it available to Lender at a place designated by Lender that is reasonably convenient to Lender and Borrower. The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied by Lender in the following order of priorities:
First, to Lender in an amount sufficient to pay in full Lender’s costs and professionals’ and advisors’ fees and expenses as described in Section 11.11;
Second, to Lender in an amount equal to the then unpaid amount of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order and priority as Lender may choose in its sole discretion; and
Finally, after the full and final payment in Cash of all of the Secured Obligations, to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct.
Lender shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a secured party under the UCC.
10.3 The Lender agrees not to issue a notice of exclusive control or any other instruction under any Account Control Agreement unless an Event of Default has occurred and is continuing.
10.4 No Waiver. Lender shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and Borrower expressly waives all rights, if any, to require Lender to marshal any Collateral.
10.5 Cumulative Remedies. The rights, powers and remedies of Lender hereunder shall be in addition to all rights, powers and remedies given by statute or rule of
24
law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights, powers and remedies of Lender.
SECTION 11. MISCELLANEOUS
11.1 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.
11.2 Notice. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) (a “Notification”) that is required, contemplated, or permitted under the Loan Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery or delivery by an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, in each case addressed to the party to be notified as follows:
(a) If to Lender:
HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Legal Department
Attention: Chief Legal Officer and Xxxxxx Xxxxxxx
000 Xxxxxxxx Xxxxxx, Xxxxx 000
Xxxx Xxxx, XX 00000
Facsimile: 000-000-0000
Telephone: 000-000-0000
With a copy to:
HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
00 Xx. Xxxxx Xxx., Xxxxx 000
Xxxxxx, XX 00000
Attention: Xxxxxx Xxxxxxx
Facsimile: 617-
Telephone: 000-000-0000
(b) If to Borrower:
00 Xxxxxx Xxx., Xxxxx 000
Xxxxxxxxx, XX 00000
Attention: Xxxxx Xxxxxx
Chief Operating Officer
Facsimile:
Telephone:
25
With a copy (that shall not constitute notice) to:
Xxxxxx Xxxxxx Xxxxxxxxx Xxxx and Xxxx LLP.
00 Xxxxx Xxxxxx
Xxxxxx, XX 00000
Attention: Xxxxx X. Xxxxxxx
Facsimile: 000-000-0000
Telephone: 000-000-0000
or to such other address as each party may designate for itself by like notice. Any notification delivered to a party to this Agreement in accordance with this Section shall be valid notwithstanding any failure to deliver a copy thereof to a Person not party to this Agreement.
11.3 Entire Agreement; Amendments. This Agreement, the Notes, and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof or thereof (including Lender’s revised proposal letter dated October 12, 2011). None of the terms of this Agreement, the Notes or any of the other Loan Documents may be amended except by an instrument executed by each of the parties hereto.
11.4 No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.
11.5 No Waiver. The powers conferred upon Lender by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Lender to exercise any such powers. No omission or delay by Lender at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Lender is entitled, nor shall it in any way affect the right of Lender to enforce such provisions thereafter.
11.6 Survival. All agreements, representations and warranties contained in this Agreement, the Notes and the other Loan Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Lender and shall survive the execution and delivery of this Agreement and Section 6.3 and any provisions that, by their express terms are to survive the expiration or other termination of this Agreement shall survive such expiration or termination.
26
11.7 Successors and Assigns. The provisions of this Agreement and the other Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any). Borrower shall not assign its obligations under this Agreement, the Notes or any of the other Loan Documents without Lender’s express prior written consent, and any such attempted assignment shall be void and of no effect. Lender may assign, transfer, or endorse its rights hereunder and under the other Loan Documents to an Assignee (defined in Section 11.13) without prior notice to Borrower or Borrower’s consent, and all of such rights shall inure to the benefit of Lender’s successors and assigns.
11.8 Governing Law. This Agreement, the Notes and the other Loan Documents have been negotiated and delivered to Lender in the Commonwealth of Massachusetts, and shall have been accepted by Lender in the Commonwealth of Massachusetts. Payment to Lender by Borrower of the Secured Obligations is due in the Commonwealth of Massachusetts. This Agreement, the Notes and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the Commonwealth of Massachusetts, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.
11.9 Consent to Jurisdiction and Venue. All judicial proceedings (to the extent that the reference requirement of Section 11.10 is not applicable) arising in or under or related to this Agreement, the Notes or any of the other Loan Documents may be brought in any state or federal court located in the Commonwealth of Massachusetts. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to exclusive personal jurisdiction in Suffolk County, Commonwealth of Massachusetts; (b) waives any objection as to jurisdiction or venue in the Business Litigation Session of the Suffolk Superior Court, Suffolk County, Commonwealth of Massachusetts; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement, the Notes or the other Loan Documents. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 11.2, and shall be deemed effective and received as set forth in Section 11.2. Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.
11.10 Mutual Waiver of Jury Trial / Judicial Reference.
(a) Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF BORROWER AND LENDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM,
27
COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY BORROWER AGAINST LENDER OR ITS ASSIGNEE OR BY LENDER OR ITS ASSIGNEE AGAINST BORROWER. This waiver extends to all such Claims, including Claims that involve Persons other than Borrower and Lender; Claims that arise out of or are in any way connected to the relationship between Borrower and Lender; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document.
11.11 Professional Fees. Borrower promises to pay Lender’s fees and expenses necessary to finalize the loan documentation, including but not limited to reasonable attorneys fees, UCC searches, filing costs, and other reasonable miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable attorneys’ and other reasonable professionals’ fees and expenses incurred by Lender after the Closing Date in connection with or related to: (a) the Loan; (b) the administration, collection, or enforcement of the Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents; (e) the protection, preservation, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Lender in any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower’s estate, and any appeal or review thereof.
11.12 Confidentiality. Lender acknowledges that certain items of Collateral and information provided to Lender by Borrower are confidential or proprietary information of Borrower, if and to the extent such information either (x) is marked as confidential, proprietary or secret by Borrower at the time of disclosure, or (y) should reasonably be understood to be confidential, proprietary or secret (the “Confidential Information”). Accordingly, Lender agrees that any Confidential Information it may obtain in the course of acquiring, administering, perfecting or enforcing Lender’s security interest in the Collateral or otherwise shall not be disclosed to any other person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Lender may disclose any such information: (a) to its own directors, officers, employees, accountants, counsel and other professional advisors and to its controlled affiliates if Lender in its sole discretion determines that any such party should have access to such information in connection with such party’s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information; (b) if such information is generally available to the public without any disclosure by Lender or breach of this Section 11.12; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Lender; (d) if required or appropriate in
28
response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Lender’s counsel; (e) to comply with any legal requirement or law applicable to Lender; (f) to the extent reasonably necessary in connection with the exercise of any right or remedy under any Loan Document, including Lender’s sale, lease, or other disposition of Collateral during the continuation of an Event of Default; (g) to any participant or assignee of Lender or any prospective participant or assignee; provided, that such participant or assignee or prospective participant or assignee agrees in writing to be bound by this Section prior to disclosure; or (h) otherwise with the prior written consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its affiliates or any guarantor under this Agreement or the other Loan Documents.
11.13 Assignment of Rights. Borrower acknowledges and understands that Lender may sell and assign all or part of its interest hereunder and under the Note(s) and Loan Documents (an “Assignment”) to any person or entity provided that (a) no such Assignment shall be made to a competitor of the Borrower, and (b) Lender will not make any Assignment to a Person organized or resident outside the United States without Borrower’s consent which shall not be unreasonably withheld (such assignee, an “Assignee” or “assignee”). After such assignment the term “Lender” as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Lender hereunder with respect to the interest so assigned; but with respect to any such interest not so transferred, Lender shall retain all rights, powers and remedies hereby given. No such assignment by Lender shall relieve Borrower of any of its obligations hereunder. No such Assignment shall release the Lender from its obligations to fund the Term Advance subject to the terms and conditions contained in Section 2.1 hereof. Lender agrees that in the event of any transfer by it of the Note(s), it will endorse thereon a notation as to the portion of the principal of the Note(s), which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon.
11.14 Revival of Secured Obligations. This Agreement and the Loan Documents shall remain in full force and effect and continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower’s assets, or if any payment or transfer of Collateral is recovered from Lender. The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Lender, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Lender or by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment, performance, or transfer of Collateral had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Lender in Cash.
29
11.15 Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument.
11.16 No Third Party Beneficiaries. No provisions of the Loan Documents are intended, nor will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any person other than Lender and Borrower unless specifically provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will be personal and solely between the Lender and the Borrower.
11.17 Publicity. Subject to applicable law, Lender may use Borrower’s name and logo, and include a brief description of the relationship between Borrower and Lender, in Lender’s marketing materials, provided that the Borrower shall have the right to review such use prior to publication.
(SIGNATURES TO FOLLOW)
30
IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.
| BORROWER: | ||
| CONCERT PHARMACEUTICALS, INC. | ||
| Signature: | /s/ Xxxxx X. Xxxx | |
|
| ||
| Print Name: | Xxxxx X. Xxxx | |
| Title: | Chief Executive Officer | |
Accepted in Boston, Massachussets:
| LENDER: | ||
| HERCULES TECHNOLOGY GROWTH CAPITAL, INC. | ||
| By: |
| |
| Name: |
| |
| Its: |
| |
IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.
| BORROWER: | ||||||
| CONCERT PHARMACEUTICALS, INC. | ||||||
| Signature: |
| |||||
| Print Name: |
| |||||
| Title: |
| |||||
| Accepted in Boston, Massachussets: | ||||||
| LENDER: | ||
| HERCULES TECHNOLOGY GROWTH CAPITAL, INC. | ||
| By: | /s/ X. Xxxxxxxx Martitsch | |
|
| ||
| Name: | X. Xxxxxxxx Martitsch | |
| Its: | Associate General Counsel | |
31
Table of Exhibits and Schedules
| Exhibit A: | Advance Request | |
| Attachment to Advance Request | ||
| Exhibit B-1: | Term Note | |
| Exhibit C: | Name, Locations, and Other Information for Borrower | |
| Exhibit D: | Borrower’s Patents, Trademarks, Copyrights and Licenses | |
| Exhibit E: | Borrower’s Deposit Accounts and Investment Accounts | |
| Exhibit F: | Compliance Certificate | |
| Exhibit G: | Joinder Agreement | |
| Exhibit H: | ACH Debit Authorization Agreement | |
| Schedule 1 | Subsidiaries | |
| Schedule 1A | Existing Permitted Indebtedness | |
| Schedule 1B | Existing Permitted Investments | |
| Schedule 1C | Existing Permitted Liens | |
| Schedule 5.3 | Consents, Etc. | |
| Schedule 5.5 | Actions Before Governmental Authorities | |
| Schedule 5.8 | Tax Matters | |
| Schedule 5.9 | Intellectual Property Claims | |
| Schedule 5.10 | Intellectual Property | |
| Schedule 5.11 | Borrower Products | |
| Schedule 5.14 | Capitalization | |
1
EXHIBIT A
ADVANCE REQUEST
| To: | Date: , 201 |
Hercules Technology Growth Capital, Inc.
000 Xxxxxxxx Xxxxxx, Xxxxx 000
Xxxx Xxxx, XX 00000
Facsimile: 000-000-0000
Attn: Xxxxxx Xxxxxxx
CONCERT PHARMACEUTICALS, INC. (“Borrower”) hereby requests from Hercules Technology Growth Capital, Inc. (“Lender”) an Advance in the amount of Dollars ($ ) on , (the “Advance Date”) pursuant to the Loan and Security Agreement between Borrower and Lender (the “Agreement”). Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement.
Please:
| (a) | Issue a check payable to Borrower |
|
||||||
| or | ||||||||
| (b) | Wire Funds to Borrower’s account |
|
||||||
| Bank: |
|
|||||||
| Address: |
|
|||||||
|
|
||||||||
| ABA Number: |
|
|||||||
| Account Number: |
|
|||||||
| Account Name: |
|
|||||||
Borrower represents that the conditions precedent to the Advance set forth in the Agreement are satisfied and shall be satisfied upon the making of such Advance, including but not limited to: (i) that no Material Adverse Effect has occurred and is continuing; (ii) No Material Adverse Effect has occurred and is continuing; (iii) that the representations and warranties set forth in the Agreement are true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date; (iv) that Borrower is in compliance in all material respects with all the terms and provisions set forth in each Loan Document on its part to be observed or performed; and (v) that as of the Advance Date, no fact or condition exists that constitutes (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default under the Loan Documents. Borrower understands and acknowledges that Lender has the right to review the financial information supporting this representation and, based upon such review in its sole discretion, Lender may decline to fund the requested Advance if such representation is not true and correct in all material respects.
2
Borrower hereby represents that the information described in Exhibit C to the Loan Agreement have not changed since the date of the Agreement or, if the Attachment to this Advance Request is completed, are as set forth in the Attachment to this Advance Request.
Borrower agrees to notify Lender promptly before the funding of the Loan if any of the matters which have been represented above shall not be true and correct on the Borrowing Date and if Lender has received no such notice before the Advance Date then the statements set forth above shall be deemed to have been made and shall be deemed to be true and correct as of the Advance Date.
Executed as of , 201 .
| BORROWER: | ||
| CONCERT PHARMACEUTICALS, INC. | ||
| SIGNATURE: |
| |
| TITLE: |
|
| PRINT NAME: |
|
3
ATTACHMENT TO ADVANCE REQUEST
Dated:
Borrower hereby represents and warrants to Lender that Borrower’s current name and organizational status is as follows:
| Name: | CONCERT PHARMACEUTICALS, INC. | |
| Type of organization: | Corporation | |
| State of organization: | Delaware | |
| Organization file number: | 4141420 | |
Borrower hereby represents and warrants to Lender that xxx xxxxxx xxxxxxxxx, xxxxxx, xxxxxx and postal codes of its current owned and leased locations are as follows:
4
EXHIBIT B-1
SECURED TERM PROMISSORY NOTE
| $ | Advance Date: , 201 | |
| Maturity Date: July 1, 2015 | ||
FOR VALUE RECEIVED, CONCERT PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”) hereby promises to pay to the order of Hercules Technology Growth Capital, Inc. or the holder of this Note (the “Lender”) at 000 Xxxxxxxx Xxxxxx, Xxxxx 000, Xxxx Xxxx, XX 00000 or such other place of payment as the holder of this Secured Term Promissory Note (this “Promissory Note”) may specify from time to time in writing, in lawful money of the United States of America, the principal amount of ($ ) or such other principal amount as Lender has advanced to Borrower, together with interest at a floating rate equal to the greater of (a) 8.50% per annum and (b) 8.50% plus the United States Prime Rate as reported in The Wall Street Journal minus 5.25%, not in any case to exceed 11.0% per annum, based upon a year consisting of 360 days, with interest computed daily based on the actual number of days in each month.
This Promissory Note is the Note referred to in, and is executed and delivered in connection with, that certain Loan and Security Agreement dated December , 2011, by and between Borrower and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions thereof. All payments shall be made in accordance with the Loan Agreement. All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement shall constitute a default under this Promissory Note.
Borrower waives presentment and demand for payment, notice of dishonor, protest and notice of protest under the UCC or any applicable law. Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense. This Promissory Note has been negotiated and delivered to Lender and is payable in the Commonwealth of Massachusetts. This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the Commonwealth of Massachusetts, excluding any conflicts of law rules or principles that would cause the application of the laws of any other jurisdiction.
| BORROWER: | CONCERT PHARMACEUTICALS, INC. | |||||
| By: |
| |||||
| Title: |
| |||||
EXHIBIT C
NAME, LOCATIONS, AND OTHER INFORMATION FOR BORROWER
1. Borrower represents and warrants to Lender that Borrower’s current name and organizational status as of the Closing Date is as follows:
| Name: | CONCERT PHARMACEUTICALS, INC. | |
| Type of organization: | Corporation | |
| State of organization: | Delaware | |
| Organization file number: | 4141420 | |
2. Borrower represents and warrants to Lender that for five (5) years prior to the Closing Date, Borrower did not do business under any other name or organization or form except the following:
Name: Concert Pharmaceuticals, Inc.
Used during dates of: Five (5) years prior to the Closing
Type of Organization: Corporation
State of organization: Delaware
Organization file Number: 4141420
Borrower’s fiscal year ends on: December 31
Borrower’s federal employer tax identification number is: 00-0000000
3. Borrower represents and warrants to Lender that its chief executive office is located at 00 Xxxxxx Xxxxxx, Xxxxx 000 & 000, Xxxxxxxxx, XX 00000.
EXHIBIT D
BORROWER’S PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES
See attached.
| Title | Application Number | Filing Date | ||||
| 1 | 4-Hydroxybutyric Acid Analogs | |||||
| United States of America |
61/442451 | February 14, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
61/484296 | May 10, 2011 | ||||
| Canada |
2740247 | May 13, 0000 | ||||
| Xxxxxxxxx |
2011200745 | February 22, 0000 | ||||
| Xxxxxx |
2732479 | February 23, 0000 | ||||
| Xxxxxxxxx |
2011202741 | June 8, 2011 | ||||
| 2 | 4-Hydroxybutyric Acid Analogs | |||||
| Patent Cooperation Treaty |
PCT/US2010/031981 | April 22, 0000 | ||||
| Xxxxxxxxx |
0000000000 |
October 23, 2011 | ||||
| European Patent Convention |
10716196 | October 23, 0000 | ||||
| Xxxxxx Xxxxxx of America |
13/265609 |
October 23, 0000 | ||||
| Xxxxxx |
NEW APPLICATION | Xxxxxxx 00, 0000 | ||||
| Xxxxx |
8456/DELNP/2011 |
October 23, 2011 | ||||
| 3 | Alpha 1A-adrenoceptor antagonists | |||||
| United States of America |
12/072,501 | February 26, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/550864 | February 26, 0000 | ||||
| Xxxxxx Xxxxxx of America |
13/189080 | July 22, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2008/002513 | February 26, 2008 | ||||
| European Patent Convention |
8726096.4 | February 26, 2008 | ||||
| 4 | Analogues of cilostazol | |||||
| United States of America |
12/150107 | April 24, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/644758 | December 22, 2009 | ||||
| Patent Cooperation Treaty |
PCT/US2008/005301 | April 24, 2008 | ||||
| European Patent Convention |
8743256.3 | April 24, 2008 | ||||
| 0 | Xxxxxxxxxxxxxxxxx xxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
61/481977 | May 3, 2011 | ||||
| 6 | Derivatives of dimethylcurcumin | |||||
| United States of America |
13/049481 | March 16, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2011/028631 | March 16, 2011 | ||||
| 7 | Deuterated 2-amino-3-hydroxypropanoic acid derivatives | |||||
| United States of America |
13/119318 | March 16, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2009/057001 | September 15, 2009 | ||||
| European Patent Convention |
9792561.4 | September 15, 2009 | ||||
| 8 | Deuterated Benzo[D][1,3]-dioxol derivatives | |||||
| United States of America |
12/688466 | January 15, 2010 | ||||
Page 1 of 16
| Title | Application Number | Filing Date | ||||
| 9 | Deuterated CFTR potentiators | |||||
| United States of America |
61/487497 | May 18, 2011 | ||||
| 10 | Deuterated fingolimod | |||||
| United States of America |
12/290645 | October 31, 2008 | ||||
| Patent Cooperation Treaty |
PCT/US2008/012390 | October 31, 2008 | ||||
| European Patent Convention |
8847117.2 | October 31, 2008 | ||||
| Hong Kong |
11101551.6 | |||||
| Japan |
2010-532064 | October 31, 0000 | ||||
| Xxxxxx Xxxxxx of America |
13/311171 | 05-Dec-2011 | ||||
| 11 | Deuterated isoindoline-1,3-dione derivatives as PDE4 and TNF-alpha inhibitors | |||||
| Patent Cooperation Treaty |
PCT/US2010/038577 | June 15, 0000 | ||||
| Xxxxxxxxx |
instructions to file sent | December 6, 0000 | ||||
| Xxxxxx |
instructions to file sent | December 6, 0000 | ||||
| Xxxxxx |
instructions to file sent | December 6, 2011 | ||||
| China (People’s Republic) |
201010620532.7 | December 22, 2010 | ||||
| Eurasian Patent Organization |
instructions to file sent | December 6, 2011 | ||||
| European Patent Convention |
instructions to file sent | Xxxxxxxx 0, 0000 | ||||
| Xxxxx |
instructions to file sent | December 6, 0000 | ||||
| Xxxxx |
instructions to file sent | Xxxxxxxx 0, 0000 | ||||
| Xxxxx, Xxxxxxxx of |
00-0000-0000000 | December 22, 2010 | ||||
| 00 | Xxxxxxxxxxx xxxxxxxxxxx-0,0-xxxxx xxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
12/816295 | June 15, 0000 | ||||
| Xxxxx, Xxxxxxxx of |
00-0000-0000000 | Xxxxxxxx 00, 0000 | ||||
| Xxxxx (People’s Republic) |
2.01011E+11 | December 22, 2010 | ||||
| 00 | Xxxxxxxxxx xxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
13/132784 | December 3, 2009 | ||||
| Patent Cooperation Treaty |
PCT/US2009/066606 | December 3, 2009 | ||||
| 14 | Fluorinated diaryl urea derivatives | |||||
| United States of America |
13/320646 | 15-Nov-2011 | ||||
| Patent Cooperation Treaty |
PCT/US2010/035655 | May 20, 2010 | ||||
| 15 | Fluorouracil derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2011/026436 | February 28, 2011 | ||||
| 16 | Method of utilizing recycled deuterium oxide in the synthesis of deuterated compounds | |||||
| Patent Cooperation Treaty |
PCT/US2011/050134 | September 1, 2011 | ||||
Page 2 of 16
| Title | Application Number | Filing Date | ||||
| 17 | Niacin prodrugs and deuterated versions thereof | |||||
| United States of America |
12/948484 | November 17, 2010 | ||||
| Patent Cooperation Treaty |
PCT/US2010/057051 | November 17, 2010 | ||||
| 18 | Novel benzo[D][1,3]-dioxol derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2006/029599 | July 28, 0000 | ||||
| Xxxxxxxxx |
2006275595 | July 28, 0000 | ||||
| Xxxxxx |
PI0615973-7 | July 28, 0000 | ||||
| Xxxxxx |
2616383 | July 28, 0000 | ||||
| Xxxxx (People’s Republic) |
2.0068E+11 | July 28, 2006 | ||||
| Eurasian Patent Organization |
200800490 | July 28, 2006 | ||||
| European Patent Convention |
6813250.5 | July 28, 2006 | ||||
| Hong Kong |
8111437 | July 28, 2006 | ||||
| India |
607/DELNP/2008 | July 28, 0000 | ||||
| Xxxxx |
2008-524227 | July 28, 0000 | ||||
| Xxxxx, Xxxxxxxx of |
00-0000-0000000 | July 28, 0000 | ||||
| Xxxxxx |
MX/a/2008/001193 | July 28, 0000 | ||||
| Xxxxxxxxxxx |
0-0000-000000 | July 00, 0000 | ||||
| Xxxxx Xxxxxx |
2008/00785 | July 28, 0000 | ||||
| Xxxxxx Xxxxxx of America |
11/704554 | February 8, 2007 | ||||
| 19 | Novel tetrahydro-1H-pyrido[4,3-B]indoles | |||||
| United States of America |
12/625059 | November 24, 2009 | ||||
| Patent Cooperation Treaty |
PCT/US2009/065872 | November 25, 2009 | ||||
| 20 | Oxazolidinone derivatives and methods of use | |||||
| United States of America |
12/214260 | June 17, 2008 | ||||
| Patent Cooperation Xxxxxx |
XXX/XX0000/000000 | Xxxxxxx 00, 0000 | ||||
| Xxxx Xxxx |
10102539.2 | October 23, 0000 | ||||
| Xxxxx |
2009-533406 | October 23, 2007 | ||||
| 21 | Polymorphs of (S)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1H-purine-2,6(3H,7H)-dione | |||||
| Patent Cooperation Treaty |
PCT/US2011/050229 | September 1, 2011 | ||||
| 22 | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation | |||||
| Patent Cooperation Treaty |
PCT/US2011/050138 | September 1, 2011 | ||||
Page 3 of 16
| Title | Application Number | Filing Date | ||||
| 23 | Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation | |||||
| Patent Cooperation Treaty |
PCT/US2011/050139 | September 1, 2011 | ||||
| 24 | Prostacyclin analogs | |||||
| Patent Cooperation Treaty |
PCT/US2009/003801 | June 26, 0000 | ||||
| Xxxxxx Xxxxxx of America |
13/001543 | March 31, 2011 | ||||
| 25 | Prostacyclin analogs | |||||
| Patent Cooperation Treaty |
PCT/US2007/026264 | December 21, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/520493 | December 21, 0000 | ||||
| Xxxxxx Xxxxxx of America |
12/489425 | June 22, 0000 | ||||
| Xxxxx |
2009-542961 | December 21, 0000 | ||||
| Xxxxxxxxx |
2007338701 | December 21, 0000 | ||||
| Xxxxxx |
PI0719463-3 | December 21, 2007 | ||||
| Canada |
2672904 | Xxxxxxxx 00, 0000 | ||||
| Xxxxx (People’s Republic) |
2.0078E+11 | December 21, 2007 | ||||
| Eurasian Patent Organization |
200900862 | December 21, 2007 | ||||
| European Patent Convention |
7863238.7 | Xxxxxxxx 00, 0000 | ||||
| Xxxxx |
0000/XXXXX/0000 | Xxxxxxxx 00, 0000 | ||||
| Xxxxx, Xxxxxxxx of |
00-0000-0000000 | December 21, 0000 | ||||
| Xxxxxx |
MX/a/2009/006692 | December 21, 0000 | ||||
| Xxxxx Xxxxxx |
2009/04722 | December 21, 2007 | ||||
| 26 | Prostacyclin analogs | |||||
| Patent Cooperation Treaty |
PCT/US2010/040891 | July 2, 2010 | ||||
| 00 | Xxxxxxxxxxxxxxxxxxxx xxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
61/449312 | March 4, 2011 | ||||
| 28 | Pyrazinoisoquinoline compounds | |||||
| United States of America |
61/210279 | March 17, 0000 | ||||
| Xxxxxx Xxxxxx of America |
13/256787 | September 15, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2010/027476 | March 16, 0000 | ||||
| Xxxxxxx Xxxxx Xxxxxxxxxxx (OAPI) |
NEW APPLICATION | September 15, 0000 | ||||
| Xxxxxx |
NEW APPLICATION | September 19, 2011 | ||||
| European Patent Convention |
10709147.2 | October 14, 2011 | ||||
| India |
7022/DELNP/2011 | September 14, 2011 | ||||
| African Regional Industrial Property Organization |
AP/P/2011/005932 |
|||||
| 00 | Xxxxxxxxxxxxx xxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
13/120455 | August 26, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2009/058212 | September 24, 2009 | ||||
Page 4 of 16
| Title | Application Number | Filing Date | ||||
| 30 | Pyridineamine derivatives | |||||
| Patent Cooperation Xxxxxx |
XXX/XX0000/000000 | Xxxxxxx 0, 0000 | ||||
| Xxxx Xxxx |
11100851.5 | October 2, 0000 | ||||
| Xxxxx |
2010-527991 | October 2, 2008 | ||||
| 31 | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds | |||||
| Patent Cooperation Treaty |
PCT/US2010/047557 | September 1, 2010 | ||||
| 32 | Substituted dioxopiperidinyl phthalimide derivatives | |||||
| Patent Cooperation Treaty |
PCT/US11/064409 | December 12, 2011 | ||||
| 33 | Substituted dioxopiperidinyl phthalimide derivatives | |||||
| Patent Cooperation Treaty |
PCT/US11/064238 | December 9, 2011 | ||||
| 34 | Substituted diphenylpyrazine derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2010/044704 | August 6, 2010 | ||||
| 35 | Substituted oxazolidinone derivatives | |||||
| United States of America |
12/228662 | August 14, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/189003 | July 22, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2008/009704 | August 14, 2008 | ||||
| China (People’s Republic) |
200880107169.X | August 14, 2008 | ||||
| European Patent Convention |
8795304.8 | August 14, 0000 | ||||
| Xxxxx |
2010-521032 | August 14, 2008 | ||||
| 36 | Substituted xanthine derivatives | |||||
| United States of America |
12/380579 | February 27, 2009 | ||||
| Patent Cooperation Treaty |
PCT/US2009/001305 | February 27, 2009 | ||||
| Patent Cooperation Treaty |
PCT/US2009/001294 | February 27, 0000 | ||||
| Xxxxxxxxx |
P090103281 | Xxxxxx 00, 0000 | ||||
| Xxxxxxxxx |
0000000000 | February 27, 0000 | ||||
| Xxxxxx |
XX0000000-0 | February 27, 2009 | ||||
| Canada |
2716788 | February 27, 0000 | ||||
| Xxxxx (People’s Republic) |
February 27, 2009 | |||||
| Eurasian Patent Organization |
201001391 | February 27, 2009 | ||||
| European Patent Convention |
9715566.7 | February 27, 2009 | ||||
| Hong Kong |
11104595.8 | May 9, 2011 | ||||
| India |
6533/DELNP/2010 | February 27, 0000 | ||||
| Xxxxx |
2010-548745 | Xxxxxxxx 00, 0000 | ||||
| Xxxxx, Xxxxxxxx of |
00-0000-0000000 | February 27, 0000 | ||||
| Xxxxxx |
MX/a/2010/009300 | Xxxxxxxx 00, 0000 | ||||
| Xxxxxxxx |
787/2009 | Xxxxxx 00, 0000 | ||||
| Xxxxx Xxxxxx |
2010/06104 | February 27, 2009 | ||||
| Taiwan |
98128631 | August 26, 2009 | ||||
| Venezuela |
2009-001574 | August 25, 2009 | ||||
Page 5 of 16
| Title | Application Number | Filing Date | ||||
| 37 | Pharmaceutically acceptable salt of a substituted oxo(or hydroxy)hexyl-1H-purine-2,6(3H,7H)-dione compound | |||||
| Pakistan |
390/2010 | August 25, 2009 | ||||
| 38 | Substituted xanthine derivatives | |||||
| United States of America |
12/874049 | September 1, 2010 | ||||
| Patent Cooperation Treaty |
PCT/US2010/047574 | September 1, 2010 | ||||
| 39 | Substituted xanthine derivatives | |||||
| United States of America |
12/873991 | September 1, 0000 | ||||
| Xxxxxx Xxxxxx of America |
12/874783 | September 2, 2010 | ||||
| Patent Cooperation Treaty |
PCT/US2010/047708 | September 2, 2010 | ||||
| 40 | Substituted xanthine derivatives | |||||
| Hong Kong |
11104593 | May 9, 0000 | ||||
| Xxxxxxxxxxx |
0-0000-000000 | February 27, 0000 | ||||
| Xxxxx |
2010-548747 | February 27, 2009 | ||||
| European Patent Convention |
9714926.4 | February 27, 2009 | ||||
| 41 | Substituted xanthine derivatives | |||||
| United States of America |
61/509343 | July 19, 2011 | ||||
| 42 | Synthesis of deuterated catechols and benzo[D][1,3] dioxoles and derivatives thereof | |||||
| Patent Cooperation Treaty |
PCT/US2008/010643 | September 12, 0000 | ||||
| Xxxxxxxxx |
2008299921 | September 12, 0000 | ||||
| Xxxxxx |
2698808 | September 12, 0000 | ||||
| Xxxxx (People’s Republic) |
2.0088E+11 | September 12, 2008 | ||||
| European Patent Convention |
8830527.1 | September 12, 2008 | ||||
| Hong Kong |
10112245.6 | Xxxxxxxx 00, 0000 | ||||
| Xxxxx |
2015/DELNP/2010 | September 12, 0000 | ||||
| Xxxxx |
2010-524866 | September 12, 0000 | ||||
| Xxxxxx |
MX/a/2010/002692 | September 12, 0000 | ||||
| Xxxxxx Xxxxxx of America |
12/283621 | September 12, 2008 | ||||
| 43 | Synthesis of deuterated morpholine derivatives | |||||
| United States of America |
12/456507 | June 17, 2009 | ||||
| Patent Cooperation Treaty |
PCT/US2009/003628 | June 17, 2009 | ||||
Page 6 of 16
| Title | Application Number | Filing Date | ||||
| 44 | Substituted dioxopiperidinyl phthalimide derivatives | |||||
| United States of America |
13/107873 | May 13, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2011/045629 | July 27, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2009/006105 | November 13, 0000 | ||||
| Xxxxxxxxx |
2009314568 | May 17, 0000 | ||||
| Xxxxxx |
PI0915267-9 | May 12, 2011 | ||||
| Canada |
2743902 | May 13, 0000 | ||||
| Xxxxx (People’s Republic) |
2.0098E+11 | November 13, 2009 | ||||
| Eurasian Patent Organization |
201100750 | June 10, 2011 | ||||
| European Patent Convention |
9826438.5 | Xxxx 0, 0000 | ||||
| Xxxxx |
1038/MUMNP/2011 | May 23, 0000 | ||||
| Xxxxx |
2011-536328 | May 00, 0000 | ||||
| Xxxxx, Xxxxxxxx of |
00-0000-0000000 | June 14, 0000 | ||||
| Xxxxxx |
MX/a/2011/005112 | May 13, 0000 | ||||
| Xxxxxxxxxxx |
0-0000-000000 | November 00, 0000 | ||||
| Xxxxx Xxxxxx |
2011/04361 | June 10, 2011 | ||||
| 45 | Azapeptide derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2008/007331 | June 12, 2008 | ||||
| European Patent Convention |
08252023.0 | June 12, 0000 | ||||
| Xxxxxxxxx |
P080102501 | June 12, 2008 | ||||
| Pakistan |
6842008 | June 12, 2008 | ||||
| Taiwan |
97122018 | June 12, 2008 | ||||
| Venezuela |
2008001156 | June 12, 2008 | ||||
| Hong Kong |
09105433.5 | June 17, 2009 | ||||
| European Patent Convention |
09075359.1 | June 12, 0000 | ||||
| Xxxxxxxxx |
2008267048 | June 12, 0000 | ||||
| Xxxxxx |
PI08139113 | June 12, 2008 | ||||
| Canada |
2692028 | Xxxx 00, 0000 | ||||
| Xxxxx (People’s Republic) |
200880021601.3 | June 12, 0000 | ||||
| Xxxxxxxx |
00000000 | Xxxx 00, 0000 | ||||
| Xxxxx |
8182DELNP2009 | June 12, 0000 | ||||
| Xxxxx |
0000000000 | June 12, 2008 | ||||
| Mexico |
MXa2009013565 | June 12, 0000 | ||||
| Xxxxx Xxxxxx |
200909079 | Xxxx 00, 0000 | ||||
| Xxxxx, Xxxxxxxx of |
1020107000675 | June 12, 0000 | ||||
| Xxxxxxxxxxx |
08252023.0 | June 12, 0000 | ||||
| Xxxxxxx |
08252023.0 | June 12, 0000 | ||||
| Xxxxx |
08252023.0 | June 12, 0000 | ||||
| Xxxxxx |
08252023.0 | June 12, 0000 | ||||
| Xxxxxx Xxxxxxx |
08252023.0 | June 12, 0000 | ||||
| Xxxxx |
08252023.0 | June 12, 2008 | ||||
| Hong Kong |
10104316.7 | April 30, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/755,184 | April 6, 2010 | ||||
| European Patent Convention |
11155667.6 | June 12, 2008 | ||||
| Hong Kong |
11109198.8 | Xxxxxx 00, 0000 | ||||
| Xxxxx (People’s Republic) |
2.0111E+11 |
June 12, 0000 | ||||
| Xxxxxx |
(divisional) instructions to file sent | |||||
Page 7 of 16
| Title | Application Number | Filing Date | ||||
| 46 | 4-oxoquinoline derivatives | |||||
| United States of America |
12/283,620 | September 12, 2008 | ||||
| Patent Cooperation Treaty |
PCT/US2008/010662 | September 12, 0000 | ||||
| Xxxxxxxxx |
2008299931 | September 12, 0000 | ||||
| Xxxxxx |
2698825 | September 12, 2008 | ||||
| European Patent Convention |
08830735.0 | Xxxxxxxxx 00, 0000 | ||||
| Xxxxx |
2377DELNP2010 | September 12, 2008 | ||||
| Mexico |
MXA2010002679 | September 12, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/153,952 | June 6, 2011 | ||||
| 47 | Deuterated darunavir | |||||
| Patent Cooperation Treaty |
PCT/US2008/012079 | October 24, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/387,327 | Xxxxx 00, 0000 | ||||
| Xxxxxxxxx |
2008317375 | October 24, 0000 | ||||
| Xxxxxx |
2703591 | October 24, 2008 | ||||
| European Patent Convention |
08843302.4 | October 24, 2008 | ||||
| 48 | Peptides for the treatment of HCV infections | |||||
| Patent Cooperation Treaty |
PCT/US2008/012949 | November 20, 2008 | ||||
| European Patent Convention |
08851195.1 | November 20, 0000 | ||||
| Xxxxx |
2010534960 | November 20, 2008 | ||||
| Hong Kong |
11101960.1 | February 28, 2011 | ||||
| 49 | Endothelin receptor antagonists | |||||
| United States of America |
12/008,698 | January 11, 2008 | ||||
| Patent Cooperation Treaty |
PCT/US2008/000384 | January 11, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/460,575 | July 20, 2009 | ||||
| 50 | Selective endothelin type-A antagonists | |||||
| Patent Cooperation Treaty |
PCT/US2008/001358 | February 1, 2008 | ||||
| European Patent Convention |
8713376.5 | February 1, 2008 | ||||
| 51 | Deuterated piperazine derivatives as anti-anginal compounds | |||||
| United States of America |
12/075,107 | March 7, 2008 | ||||
| Patent Cooperation Treaty |
PCT/US2008/003183 | March 7, 2008 | ||||
| European Patent Convention |
08726679.7 | Xxxxx 0, 0000 | ||||
| Xxxxx |
2009552765 | Xxxxx 0, 0000 | ||||
| Xxxxxxx |
08726679.7 | Xxxxx 0, 0000 | ||||
| Xxxxxx |
08726679.7 | Xxxxx 0, 0000 | ||||
| Xxxxxxx |
08726679.7 | Xxxxx 0, 0000 | ||||
| Xxxxxx Xxxxxxx |
08726679.7 | Xxxxx 0, 0000 | ||||
| Xxxxx |
08726679.7 | Xxxxx 0, 0000 | ||||
| Xxxxx |
08726679.7 | Xxxxx 0, 0000 | ||||
| Xxxxxxxxxxx |
08726679.7 | March 7, 2008 | ||||
Page 8 of 16
| Title | Application Number | Filing Date | ||||
| 52 | Tricyclic benzo[5,6]cyclonepta[1, 2- B]pyridine derivatives and uses thereof | |||||
| Patent Cooperation Treaty |
PCT/US2009/002372 | April 16, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/937,933 | April 16, 2009 | ||||
| 00 | Xxxxxxxxxx xxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
12/386,492 | April 17, 2009 | ||||
| Patent Cooperation Treaty |
PCT/US2009/002424 | April 17, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/603,380 | October 21, 2009 | ||||
| 54 | Xanthenone-4-acetic acid derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2009/060996 | October 16, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/124,626 | October 16, 2009 | ||||
| 55 | Hydroxyethlamino sulfonamide derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2009/005773 | October 23, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/125,464 | October 23, 2009 | ||||
| European Patent Convention |
09822333.2 | October 23, 2009 | ||||
| 56 | Hydroxyethylamino sulfonamide derivatives | |||||
| United States of America |
12/771,551 | April 30, 2010 | ||||
| Patent Cooperation Treaty |
PCT/US2010/033206 | April 30, 2010 | ||||
| 57 | Deuterium modified benzimidazoles | |||||
| Patent Cooperation Treaty |
PCT/US2010/034962 | May 14, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/320,653 | November 15, 2011 | ||||
| 58 | Peptides for the treatment of HCV infections | |||||
| Patent Cooperation Treaty |
PCT/US2010/036682 | May 28, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/321,785 | November 21, 2011 | ||||
| 59 | Aminoquinoline derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2011/021715 | January 19, 2011 | ||||
| 00 | Xxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
12/338,754 | December 18, 2008 | ||||
| Patent Cooperation Treaty |
PCT/US2008/087477 | December 18, 2008 | ||||
| European Patent Convention |
08862459.8 | December 18, 2008 | ||||
| 61 | Inhibitors of cholesterol ester transfer protein | |||||
| United States of America |
12/049,074 | March 14, 2008 | ||||
| Patent Cooperation Treaty |
PCT/US2008/003449 | March 14, 2008 | ||||
| Canada |
2681628 | March 14, 2008 | ||||
| European Patent Convention |
08742105.3 | March 14, 2008 | ||||
| Hong Kong |
10105723.1 | June 9, 2010 | ||||
Page 9 of 16
| Title | Application Number | Filing Date | ||||
| 62 | Synthetic triterpenoid derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2011/049163 | August 25, 2011 | ||||
| 63 | Atazanavir metabolite derivatives | |||||
| United States of America |
61/495,877 | June 10, 0000 | ||||
| 00 | Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
61/495,870 | June 10, 2011 | ||||
| 65 | Deuterated 18-methoxycoronadidine | |||||
| United States of America |
61/505,361 | July 7, 2011 | ||||
| 66 | Substituted diphenylpyrazine derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2010/044704 | August 6, 2010 | ||||
| 67 | Niacin prodrugs and deuterated versions thereof | |||||
| United States of America |
12/948,484 | November 17, 2010 | ||||
| Patent Cooperation Treaty |
PCT/US2010/057051 | November 17, 2010 | ||||
| 00 | Xxxxxxxxxxxxxx xxxxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/975,464 | December 22, 2010 | ||||
| Canada |
2701638 | April 1, 2008 | ||||
| Patent Cooperation Treaty |
PCT/US2008/059023 | April 1, 2008 | ||||
| 69 | 1,2-benzisoxazol-3-yl compounds | |||||
| United States of America |
12/102,164 | April 14, 2008 | ||||
| Patent Cooperation Treaty |
PCT/US2008/060210 | April 14, 0000 | ||||
| 00 | Xxxxxxxx(xxxxx)xxxxxxxxxx | |||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/112,722 | April 30, 2008 | ||||
| Canada |
2685924 | April 30, 2008 | ||||
| European Patent Convention |
08769252.1 | April 30, 0000 | ||||
| Xxxxx |
2009-551067 | April 30, 2008 | ||||
| Patent Cooperation Treaty |
PCT/US2008/062039 | April 30, 2008 | ||||
| 00 | Xxxxxxxxx xxxxxxxxx | |||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/112,936 | April 30, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/118,912 | May 31, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/118,935 | May 31, 0000 | ||||
| Xxxxxxxxx |
2008247818 | April 30, 0000 | ||||
| Xxxxxxxxx |
(divisional) instructions to file sent | |||||
| Brazil |
PI0811478-1 | April 30, 2008 | ||||
| Canada |
2685723 | April 30, 2008 | ||||
Page 10 of 16
| Title | Application Number | Filing Date | ||||
| China (People’s Republic) |
200880017768.2 | April 30, 2008 | ||||
| European Patent Convention |
08747238.7 | April 30, 2008 | ||||
| European Patent Convention |
11000763.0 | April 30, 2008 | ||||
| European Patent Convention |
11000764.8 | April 30, 2008 | ||||
| Hong Kong |
1010707.6 | Xxxxxx 0, 0000 | ||||
| Xxxx Xxxx |
11109618.0 | September 12, 2011 | ||||
| Hong Kong |
11109620.6 | Xxxxxxxxx 00, 0000 | ||||
| Xxxxx |
7533/DELNP/2009 | April 30, 0000 | ||||
| Xxxxx |
2010-506617 | Xxxxx 00, 0000 | ||||
| Xxxxxx |
2009/011958 | April 30, 0000 | ||||
| Xxxxxx |
MX/a/2011/010560 | October 6, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2008/062089 | April 30, 2008 | ||||
| 00 | X-xxxxxx-0-xxxxxxxxxxxxxxx xxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
12/539,091 | August 11, 2009 | ||||
| Patent Cooperation Treaty |
PCT/US2009/053384 | August 11, 2009 | ||||
| 00 | Xxxxxxxxxx xxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
12/288,186 | October 17, 2008 | ||||
| European Patent Convention |
08839230.3 | October 17, 2008 | ||||
| Hong Kong |
11101126.2 | October 17, 2008 | ||||
| Patent Cooperation Treaty |
PCT/US2008/011856 | October 17, 2008 | ||||
| 74 | Deuterated morpholinyl compounds | |||||
| United States of America |
12/106,127 | Xxxxx 00, 0000 | ||||
| Xxxxxxxxx |
2008242703 | April 18, 0000 | ||||
| Xxxxxx |
P10810362-3 | April 18, 2008 | ||||
| Canada |
2686545 | Xxxxx 00, 0000 | ||||
| Xxxxx (People’s Republic) |
200880012551.2 | April 18, 2008 | ||||
| European Patent Convention |
08746315.4 | Xxxxx 00, 0000 | ||||
| Xxxxx |
7500/DELNP/2009 | April 18, 0000 | ||||
| Xxxxx |
2010-504289 | April 18, 0000 | ||||
| Xxxxx |
2011-18410 | January 31, 2011 | ||||
| South Korea |
00-0000-0000000 | Xxxxx 00, 0000 | ||||
| Xxxxx Xxxxx |
00-0000-0000000 | September 8, 2010 | ||||
| Patent Cooperation Treaty |
PCT/US2008/060877 | April 18, 2008 | ||||
| 75 | Deuterated 2-propylpentanoic acid compounds | |||||
| European Patent Convention |
09744570.4 | October 28, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/126,384 | April 27, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2009/062397 | October 28, 2009 | ||||
| 76 | Novel pyrimidinecarboxamide derivatives | |||||
| United States of America |
12/169,367 | July 8, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/712,399 | February 25, 2010 | ||||
| Canada |
2702317 | July 8, 2008 | ||||
| Patent Cooperation Treaty |
PCT/US2008/069425 | July 8, 2008 | ||||
Page 11 of 16
| Title | Application Number | Filing Date | ||||
| 00 | Xxxxxxxxxx xxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
12/993,530 | February 10, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2009/045245 | May 27, 2009 | ||||
| 78 | Analogs of d-dextromethorphan | |||||
| Australia |
2009293123 | September 18, 0000 | ||||
| Xxxxxx |
PI0918760-0 | September 18, 2009 | ||||
| Canada |
2737811 | September 18, 2009 | ||||
| China |
200980142670.4 | September 18, 2009 | ||||
| Eurasia |
201170473 | September 18, 2009 | ||||
| European Patent Convention |
09792714.9 | September 18, 2009 | ||||
| European Patent Convention |
11188848.3 | September 18, 2009 | ||||
| Hong Kong |
N/A | Xxxxxxxxx 00, 0000 | ||||
| Xxxxx |
2116/DELNP/2011 | September 18, 2009 | ||||
| India |
(divisional) instructions to file sent | |||||
| Japan |
2011-527994 | September 18, 2009 | ||||
| South Korea |
00-0000-0000000 | September 18, 2009 | ||||
| South Korea |
00-0000-0000000 | November 18, 0000 | ||||
| Xxxxxx |
N/MX/a/2011/002994 | September 18, 2009 | ||||
| Philipines |
0-0000-000000 | September 18, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/119,905 | July 1, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2009/057476 | September 18, 0000 | ||||
| Xxxxx Xxxxxx |
2011/02113 | September 18, 2009 | ||||
| 00 | Xxxxxxxxx xxxxxxxxx | |||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/155,827 | June 8, 2011 | ||||
| 80 | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury | |||||
| European Patent Convention |
09744582.9 | October 30, 2009 | ||||
| European Patent Convention |
11180603.0 | October 30, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/126,397 | April 27, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2009/062783 | October 30, 2009 | ||||
| 81 | Methods for the treatment of neurological diseases and conditions | |||||
| European Patent Convention |
09744581.1 | October 30, 2009 | ||||
| European Patent Convention |
11180608.9 | October 30, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/126,447 | April 27, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2009/062779 | October 30, 2009 | ||||
Page 12 of 16
| Title | Application Number | Filing Date | ||||
| 82 | Substituted azaindoles | |||||
| Patent Cooperation Treaty |
PCT/US2010/056447 | November 12, 2010 | ||||
| 83 | Pyrimidine derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2011/025472 | February 18, 2011 | ||||
| 00 | Xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
13/038,533 | March 2, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2011/026787 | March 2, 2011 | ||||
| 00 | Xxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
13/227,047 | September 7, 2011 | ||||
| 86 | Novel pyrimidinecarboxamide derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2011/043872 | July 13, 2011 | ||||
| 00 | Xxxxxxxxxxx xxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
13/230,970 | September 13, 2011 | ||||
| Patent Cooperation Treaty |
PCT/US2011/051297 | September 13, 2011 | ||||
| 88 | Substituted tetracyclines | |||||
| Patent Cooperation Treaty |
PCT/US2011/060310 | November 11, 2011 | ||||
| 00 | Xxxxxxxxxx xxxxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
61/436,634 | January 27, 2011 | ||||
| 00 | 0-xxxxx-xxxxxxxxxxxxx xxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
61/446,733 | February 25, 2011 | ||||
| 00 | Xxxxxxxxxx xxxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
61/466,310 | March 22, 2011 | ||||
| 00 | Xxxxxxxxxx X-xxxxx xxxxxxxxxx | |||||
| Xxxxxx Xxxxxx of America |
61/484,412 | May 10, 2011 | ||||
| 93 | Synthetic triterpenoid derivatives | |||||
| Patent Cooperation Treaty |
US11/34984 | May 3, 2011 | ||||
| 94 | [5,6]-dihydro-2H-pyran-2-one derivatives | |||||
| Patent Cooperation Treaty |
US11/40731 | June 16, 2011 | ||||
| 95 | Derivatives of pyrazole-substituted amino-heteroaryl compounds | |||||
| United States of America |
61/448,887 | March 3, 2011 | ||||
Page 13 of 16
| Title | Application Number | Filing Date | ||||
| 96 | Novel pharmaceutical compounds | |||||
| Australia |
2006275702 | July 28, 0000 | ||||
| Xxxxx (People’s Republic) |
200680036393.50 | July 28, 0000 | ||||
| Xxxxx |
2008-524206 | July 28, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
11/704,555 | February 8, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/954,591 | November 24, 2010 | ||||
| European Patent Convention |
11155798.9 | July 28, 2006 | ||||
| 00 | Xxxxxxxx-xxxxxxxxxxxxxxxxxxx xxxxxxxxx | |||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
11/521,926 | September 14, 2006 | ||||
| 98 | Novel 1,2,3,4-tetrahydroquinoline derivatives | |||||
| United States of America |
12/296,927 | September 30, 2009 | ||||
| 99 | 3-(dihydro-1H-pyrazolo[4,3-D]pyrimidin-5-YL)-4-propoxybenzenesulfonamide derivatives and methods of use | |||||
| Korea, Republic of |
00-0000-0000000 | October 22, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
11/876,754 | October 22, 0000 | ||||
| Xxxxx |
2009-533595 | October 22, 2007 | ||||
| India |
868/MUMNP/2009 | October 22, 0000 | ||||
| Xxxxxx |
MX/a/2009/003941 | October 22, 2007 | ||||
| 000 | Xxxxxxxxxxxxxxxxx xxxxxxxxxxx | |||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/425,957 | April 17, 2009 | ||||
| 101 | Triazolyl tropane derivatives | |||||
| United States of America |
11/941,925 | November 16, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/044,534 | March 9, 2011 | ||||
| 102 | Heterocyclic kinase inhibitors | |||||
| European Patent Convention |
8859849.5 | December 9, 2008 | ||||
| Hong Kong |
11102019 | December 9, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/331,431 | December 9, 2008 | ||||
| 103 | Vandetanib derivatives | |||||
| United States of America |
12/864,219 | November 16, 2010 | ||||
| 104 | Derivatives of gefitinib | |||||
| European Patent Convention |
9703515.8 | January 22, 2009 | ||||
| Hong Kong |
10111408.1 | January 22, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/358,238 | January 22, 0000 | ||||
| Xxxxx |
2010-544356 | January 22, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/946,856 | November 15, 2010 | ||||
Page 14 of 16
| Title | Application Number | Filing Date | ||||
| 105 | Quinazoline derivatives and methods of treatment | 11/957,442 | December 15, 0000 | |||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/694,249 | January 26, 2010 | ||||
| 106 | Derivatives of 3-(2-hydroxy-5-methyphenyl)-N,N-diisopropyl-3- phenylpropylamine and methods of use thereof | |||||
| China (People’s Republic) |
200980121626.50 | Xxxxx 0, 0000 | ||||
| Xxxxx, Xxxxxxxx of |
00-0000-0000000 | April 9, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/937,262 | January 26, 0000 | ||||
| Xxxxx |
2011-504185 | April 9, 2009 | ||||
| 107 | Substituted triazolo-pyridazine derivatives | |||||
| Canada |
2735549 | August 28, 2009 | ||||
| European Patent Convention |
9810685.9 | August 28, 2009 | ||||
| Eurasian Patent Organization |
201100409 | August 28, 0000 | ||||
| Xxxxxxxxx |
2009285533 | August 28, 0000 | ||||
| Xxxxxx |
PI0912928-6 | August 28, 2009 | ||||
| China (People’s Republic) |
200980140350.50 | Xxxxxx 00, 0000 | ||||
| Xxxxx, Xxxxxxxx of |
00-0000-0000000 | Xxxxxx 00, 0000 | ||||
| Xxxxxxxxxxx |
0-0000-000000 | Xxxxxx 00, 0000 | ||||
| Xxxxx Xxxxxx |
2011/02123 | Xxxxxx 00, 0000 | ||||
| Xxxxx |
438/MUMNP/2011 | August 28, 0000 | ||||
| Xxxxx |
2011-525250 | Xxxxxx 00, 0000 | ||||
| Xxxxxx |
MX/a/2011/002278 | August 28, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/550,346 | February 4, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
13/174,662 | June 30, 2011 | ||||
| 108 | 3-(dihydro-1H-pyrazolo[4,3-D]pyrimidin-5-YL)-4-propoxybenzenesulfonamide derivatives and methods of use | |||||
| United States of America |
12/365,883 | February 4, 2009 | ||||
| 109 | Quinazoline derivatives and methods of treatment | |||||
| China (People’s Republic) |
200980118829.90 | Xxxxx 00, 0000 | ||||
| Xxxxx, Xxxxxxxx of |
00-0000-0000000 | Xxxxx 00, 0000 | ||||
| Xxxxx |
2011-502126 | Xxxxx 00, 0000 | ||||
| Xxxx Xxxx |
11108819.9 | March 27, 2009 | ||||
| 110 | 4-aminoquinazoline prodrugs | |||||
| United States of America |
12/986,135 | January 6, 2011 | ||||
Page 15 of 16
| Title | Application Number | Filing Date | ||||
| 111 | Deuterated macrocyclic inhibitors of viral NS3 protease | |||||
| United States of America |
13/092,801 | April 22, 2011 | ||||
| 112 | Substituted triazolophthalazine derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2010/045508 | August 13, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/856,360 | August 13, 2010 | ||||
| 113 | Substituted benzimidazoles | |||||
| Patent Cooperation Treaty |
PCT/US2010/052915 | October 15, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/905,835 | October 15, 2010 | ||||
| 114 | Substituted imidazotriazines | |||||
| Patent Cooperation Treaty |
PCT/US2010/043097 | July 23, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/842,589 | July 23, 2010 | ||||
| 115 | Substituted triazolo-pyridazine derivatives | |||||
| Patent Cooperation Treaty |
PCT/US2010/039497 | June 22, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/820,570 | June 22, 2010 | ||||
| 116 | 2-oxo-1-pyrrolidine derivatives | |||||
| United States of America |
13/002,267 | June 30, 2009 | ||||
| Patent Cooperation Treaty |
PCT/US09/49224 | June 30, 2009 | ||||
| 000 | Xxxxxxxxxx Xxxxxxxxx | |||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
61/496,201 | June 13, 2011 | ||||
| 118 | Analogues of cilostazol | |||||
| United States of America |
12/150,107 | April 24, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/644,758 | December 22, 2009 | ||||
| EP |
8743256.3 | November 25, 2009 | ||||
| Patent Cooperation Treaty |
PCT/US08/05301 | April 24, 2008 | ||||
| 119 | 4-aminoquinazolines | |||||
| Australia |
0000000000 | August 22, 0000 | ||||
| Xxxxxx |
2,661,223 | August 22, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
12/879,905 | September 10, 0000 | ||||
| Xxxxx (People’s Republic) |
200780093901.3 | August 22, 2007 | ||||
| European Union |
EP07811504.5 | Xxxxxx 00, 0000 | ||||
| Xxxxx |
423/MUMNP/2009 | August 22, 0000 | ||||
| Xxxxx |
2009-525631 | Xxxxxx 00, 0000 | ||||
| Xxxxxx |
MX/a/2009/001814 | August 22, 0000 | ||||
| Xxxxxx Xxxxxx xx Xxxxxxx |
11/895,174 | August 22, 2007 | ||||
| Patent Cooperation Treaty |
PCT/US2007/018655 | August 22, 2007 | ||||
| Korea |
2009-0042994 | August 22, 2007 | ||||
Page 16 of 16
Concert Pharmaceuticals, Inc. Trademarks
| COUNTRY |
XXXX |
REG. NO./ |
ISSUED/ |
GOOD/SERVICES WITH CLASS |
NOTES/ CURRENT STATUS | |||||
| Argentina | CONCERT PHARMACEUTICALS INC. | 2210582 | 01/29/2008 | Full line of pharmaceutical and biopharmaceutical preparations in Class 5 | Registered, expires 1/29/2018 | |||||
| Australia | CONCERT PHARMACEUTICALS INC. | 1157917 | 1/25/2007 | A full line of pharmaceutical and biopharmaceutical preparations in Class 5 | Registered, expires 1/25/2017 | |||||
| Australia | CONCERT PHARMACEUTICALS INC. (stylized) | 1157926 | 1/25/2007 | A full line of pharmaceutical and biopharmaceutical preparations in Class 5 | Registered, expires 1/25/2017 | |||||
| Canada | CONCERT PHARMACEUTICALS INC. | 1,332,456 | 1/24/2007 | A full line of pharmaceutical and biopharmaceutical preparations in Class 5 | Pending | |||||
| Canada | CONCERT PHARMACEUTICALS INC. (stylized) | 1,332,461 | 1/24/2007 | A full line of pharmaceutical and bio pharmaceutical preparations namely, pharmaceutical compounds for use in treating diseases and health conditions namely, pharmaceuticals for the treatment of inflammatory diseases, infectious diseases, diseases and conditions of the central nervous system, cancer, and cardiovascular disease. | Pending | |||||
| China | CONCERT PHARMACEUTICALS INC. | 5,868,162 | 3/7/2011 | Medical nutriment | Registered, expires 3/6/2021 | |||||
| China | CONCERT PHARMACEUTICALS INC. (stylized) | 5,868,163 | 3/7/2011 | Medical nutriment | Registered, expires 3/6/2021 | |||||
Concert Pharmaceuticals, Inc. Trademarks
| COUNTRY |
XXXX |
REG. NO./ |
ISSUED/ |
GOOD/SERVICES WITH CLASS |
NOTES/ CURRENT STATUS | |||||
| European Community | CONCERT PHARMACEUTICALS INC. | 5641204 | 1/30/2008 | Pharmaceutical and veterinary preparations; biopharmaceutical preparations; full line of pharmaceutical and biopharmaceutical preparations in Class 5.
Pharmaceutical research and development services in Class 42. |
Registered, expires 1/25/2017 | |||||
| European Community | CONCERT PHARMACEUTICALS INC. (stylized) | 5641295 | 1/23/2008 | Pharmaceutical and veterinary preparations; biopharmaceutical preparations; full line of pharmaceutical and biopharmaceutical preparations in Class 5. | Registered, expires 1/25/2017 | |||||
| Pharmaceutical research and development services in Class 42. | ||||||||||
| India | CONCERT PHARMACEUTICALS INC. | 1526295 | 1/25/2007 | Full line of pharmaceutical and biopharmaceutical preparations | Pending | |||||
| Israel | CONCERT PHARMACEUTICALS INC. | 197279 | 5/10/2009 | Full line of pharmaceutical and biopharmaceutical preparations in Class 5 | Registered, expires 1/25/2017 | |||||
| Japan | CONCERT PHARMACEUTICALS INC. (stylized) | 5060415 | 7/6/2007 | Pharmaceuticals in Class 5 | Registered, expires 7/6/2017 | |||||
| Japan | CONCERT PHARMACEUTICALS INC. | 5060416 | 7/6/2007 | Pharmaceuticals in Class 5 | Registered, expires 7/6/2017 | |||||
Concert Pharmaceuticals, Inc. Trademarks
| COUNTRY |
XXXX |
REG. NO./ NO. |
ISSUED/ |
GOOD/SERVICES WITH CLASS |
NOTES/ CURRENT STATUS | |||||
| New Zealand | CONCERT PHARMACEUTICALS INC. | 762543 | 7/25/2006 | Pharmaceutical and biopharmaceutical preparations but not including pharmaceutical preparations to treat hyperactivity and attention deficit disorder in children in Class 5 | Registered, expires 7/25/2016 | |||||
| Norway | CONCERT PHARMACEUTICALS INC. | 239760 | 6/20/2007 | Complete set of pharmaceutical and biopharmaceutical preparations in Class 5 | Registered, expires 6/20/17 | |||||
| Russian Federation | CONCERT PHARMACEUTICALS INC. | 346050 | 3/20/2008 | Full line of pharmaceutical and biopharmaceutical preparations in Class 5 | Registered, expires 1/25/2017 | |||||
| Singapore | CONCERT PHARMACEUTICALS INC. | T07/017771 | 1/25/2007 | Full line of pharmaceutical and biopharmaceutical preparations in Class 5 | Registered, Renewal due 1/25/2017 | |||||
| South Africa | CONCERT PHARMACEUTICALS INC. | 2007/01346 | 4/22/2010 | Full line of pharmaceutical and biopharmaceutical preparations in Class 5 | Registered, expires 1/25/2017 | |||||
| Switzerland | CONCERT PHARMACEUTICALS INC. | 559007 | 6/1/2007 | Pharmaceutical and biopharmaceutical preparations in Class 5 | Registered, expires 1/25/2017 | |||||
| Taiwan | CONCERT PHARMACEUTICALS | 1297040 | 1/16/2008 | Western medicine, biological medicine preparations in Class 5 | Registered, Renewal due 1/15/2018 | |||||
| United States | CONCERT PHARMACEUTICALS INC. | 78937102 | 7/25/2006 | Prescription pharmaceutical and biopharmaceutical preparations, namely, pharmaceutical preparations for use in treating inflammatory diseases, infectious diseases, cancer and cardiovascular disease in Class 5 | Published | |||||
Concert Pharmaceuticals, Inc. Trademarks
| COUNTRY |
XXXX |
REG. NO./ |
ISSUED/ |
GOOD/SERVICES WITH CLASS |
NOTES/ CURRENT STATUS | |||||
| Pharmaceutical research and development services in Class 42 | ||||||||||
| United States | CONCERT PHARMACEUTICALS INC. (stylized) | 78937142 | 7/25/2006 | Prescription pharmaceutical and biopharmaceutical preparations, namely, pharmaceutical preparations for use in treating inflammatory diseases, infectious diseases, cancer and cardiovascular disease in Class 5 | Published | |||||
| Pharmaceutical research and development services in Class 42 | ||||||||||
Concert Pharmaceuticals, Inc. Trademarks
| COUNTRY |
XXXX |
REG. NO./ |
ISSUED/ |
GOOD/SERVICES WITH CLASS |
NOTES/ CURRENT STATUS | |||||
| United States | DCE PLATFORM | 77907107 | 1/7/2010 | Pharmaceutical compounds for clinical study use in drug research, namely, deuterium-based compounds for research use; chemical compounds for making and studying pharmaceutical compounds, namely, deuterium-based compounds wherein each chemical compound contains one or more deuterium atoms for use in the manufacture of pharmaceutical preparations; pharmaceutical compounds for clinical study for research purposes and laboratory use in drug research, namely, deuterium-based compounds in Class 1 | Allowed | |||||
| Pharmaceutical compounds for use in treating diseases and health conditions, namely, pharmaceuticals for the treatment of treatment of inflammatory and fibrotic diseases, infectious diseases, diseases and conditions of the central nervous system, cancer, and cardiovascular and renal disease; pharmaceutical compounds for clinical study for therapeutic purposes, namely, deuterium-based compounds in Class 5 | ||||||||||
| Scientific and medical research services; medical testing services for research purposes; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; pharmaceutical research services in Class 42 | ||||||||||
EXHIBIT E
BORROWER’S DEPOSIT ACCOUNTS AND INVESTMENT ACCOUNTS
| Bank Name |
Account Number |
Branch Address |
Company/Subsidiary | |||
| Silicon Valley Bank | 3300530507 | 0000 Xxxxxx Xxxxx Xxxxx Xxxxx, XX 00000 | Company x OR Name of Sub | |||
| Silicon Valley Bank | 3300580848 | 0000 Xxxxxx Xxxxx Xxxxx Xxxxx, XX 00000 | Company x OR Name of Sub | |||
| Xxxxx Xxxxxx Xxxx | XX0000 | 0000 Xxxxx Xxxxxx Xxxxx Xxxxxx, XX 00000 | Company x OR Name of Sub | |||
| State Street Bank
Note: All cash/investments moved to DE3085. Concert requested on 12/9/11 that the DE3086 be closed. |
DE3086 | 0000 Xxxxx Xxxxxx Xxxxx Xxxxxx, XX 00000 | Company ¨ OR Name of Sub Concert Pharmaceuticals Securities Corporation | |||
| SVB Securities | 486-04255 | 0000 Xxxxxx Xxxxx Xxxxx Xxxxx, XX 00000 | Company x OR Name of Sub | |||
| SVB Securities | 486-05241 | 0000 Xxxxxx Xxxxx Xxxxx Xxxxx, XX 00000 | Company x OR Name of Sub | |||
EXHIBIT F
COMPLIANCE CERTIFICATE
Hercules Technology Growth Capital, Inc.
000 Xxxxxxxx Xxxxxx, Xxxxx 000
Xxxx Xxxx, XX 00000
Reference is made to that certain Loan and Security Agreement dated December , 2011 and all ancillary documents entered into in connection with such Loan and Security Agreement all as may be amended from time to time, (hereinafter referred to collectively as the “Loan Agreement”) between Hercules Technology Growth Capital, Inc. (“Hercules”) as Lender and CONCERT PHARMACEUTICALS, INC. (the “Company”) as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement.
The undersigned is an Officer of the Company, knowledgeable of all Company financial matters, and is authorized to provide certification of information regarding the Company; hereby certifies, in such capacity, that in accordance with the terms and conditions of the Loan Agreement, the Company is in compliance for the period ending of all covenants, conditions and terms and hereby reaffirms that all representations and warranties contained therein are true and correct in all material respects on and as of the date of this Compliance Certificate. Attached are the required documents supporting the above certification. The undersigned further certifies on behalf of the Company that these are prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year end adjustments, (iii) they do not contain certain non-cash items, and (iv) that they are subject to adjustment with respect to revenue recognition for upfront and milestone payments, and are consistent from one period to the next except as explained below.
| REPORTING REQUIREMENT | REQUIRED | CHECK IF ATTACHED | ||
| Interim Financial Statements | Monthly within 30 days | |||
| Interim Financial Statements | Quarterly within 45 days | |||
| Audited Financial Statements | FYE within 180 days | |||
| Very Truly Yours, | ||
| CONCERT PHARMACEUTICALS, INC. | ||
| By: |
| |
| Name: |
| |
| Its: |
| |
EXHIBIT G
FORM OF JOINDER AGREEMENT
This Joinder Agreement (the “Joinder Agreement”) is made and dated as of , 201 , and is entered into by and between , a corporation (“Subsidiary”), and Hercules Technology Growth Capital, Inc. as a Lender.
RECITALS
A. Subsidiary’s Affiliate, CONCERT PHARMACEUTICALS, INC. (“Company”) has entered into that certain Loan and Security Agreement dated December , 2011, with Lender, as such agreement may be amended (the “Loan Agreement”), together with the other agreements executed and delivered in connection therewith;
B. Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Company’s execution of the Loan Agreement and the other agreements executed and delivered in connection therewith;
AGREEMENT
NOW THEREFORE, Subsidiary and Lender agree as follows:
| 1. | The recitals set forth above are incorporated into and made part of this Joinder Agreement. Capitalized terms not defined herein shall have the meaning provided in the Loan Agreement. |
| 2. | By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement the same as if it were the Borrower (as defined in the Loan Agreement) under the Loan Agreement, mutatis mutandis, provided however, that Lender shall have no duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other agreements executed and delivered in connection therewith. Rather, to the extent that Lender has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other agreements executed and delivered in connection therewith, those duties, responsibilities or obligations shall flow only to Company and not to Subsidiary or any other person or entity. By way of example (and not an exclusive list): (a) Lender’s providing notice to Company in accordance with the Loan Agreement or as otherwise agreed between Company and Lender shall be deemed provided to Subsidiary; (b) a Lender’s providing an Advance to Company shall be deemed an Advance to Subsidiary; and (c) Subsidiary shall have no right to request an Advance or make any other demand on Lender. |
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
[SIGNATURE PAGE TO JOINDER AGREEMENT]
| SUBSIDIARY: | ||
|
| ||
| By: |
| |
| Name: |
| |
| Title: |
| |
| Address: |
| |
| Telephone: |
| |
| Facsimile: |
| |
| LENDER: | HERCULES TECHNOLOGY GROWTH CAPITAL, INC. | |||||
| By: |
| |||||
| Name: |
| |||||
| Its: |
| |||||
EXHIBIT H
ACH DEBIT AUTHORIZATION AGREEMENT
Hercules Technology Growth Capital, Inc.
000 Xxxxxxxx Xxxxxx, Xxxxx 000
Xxxx Xxxx, XX 00000
Re: Loan and Security Agreement dated December , 2011 between CONCERT PHARMACEUTICALS, INC. (“Borrower”) and Hercules Technology Growth Capital, Inc. (“Company”) (the “Agreement”)
In connection with the above referenced Agreement, the Borrower hereby authorizes the Company to initiate debit entries for the periodic payments due under the Agreement to the Borrower’s account indicated below. The Borrower authorizes the depository institution named below to debit to such account.
| DEPOSITORY NAME | BRANCH | |
| CITY | STATE AND ZIP CODE | |
| TRANSIT/ABA NUMBER | ACCOUNT NUMBER | |
This authority will remain in full force and effect so long as any amounts are due under the Agreement.
| CONCERT PHARMACEUTICALS, INC. | ||
| By: |
| |
| Date: |
| |
SCHEDULE 1
SUBSIDIARIES
Concert Pharmaceuticals Securities Corp., a Massachusetts corporation
SCHEDULE 1A
EXISTING PERMITTED INDEBTEDNESS
None.
SCHEDULE 1B
EXISTING PERMITTED INVESTMENTS
Investment in Concert Pharmaceuticals Securities Corp.
SCHEDULE 1C
EXISTING PERMITTED LIENS
None.
SCHEDULE 5.3
CONSENTS, ETC.
None.
SCHEDULE 5.5
ACTIONS BEFORE GOVERNMENTAL AUTHORITIES
None.
SCHEDULE 5.8
TAX MATTERS
None.
SCHEDULE 5.9
INTELLECTUAL PROPERTY CLAIMS
None.
SCHEDULE 5.10
INTELLECTUAL PROPERTY
None.
SCHEDULE 5.11
BORROWER PRODUCTS
None.
SCHEDULE 5.14
CAPITALIZATION
Borrower owns all of the outstanding capital stock of Concert Pharmaceuticals Securities Corp. See attached capitalization table of Borrower.
